A Phase 1/2 Study of a Combination of FCX-013 (Genetically-Modified Autologous Human Dermal Fibroblasts) Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)
Phase: PHASE1
Conditions: Morphea, Scleroderma, Localized, Scleroderma
Sponsor: Castle Creek Biosciences, LLC.

Protocol FI-SC-001 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
 
Confidential 
 
Page 1 of 57 
 
CLINICAL STUDY PROTOCOL 
 
 
Title: 
A Phase 1/2 Study of a Combination of FCX-013 
(Genetically-Modified Autologous Human Dermal 
Fibroblasts) plus Veledimex for the Treatment of Moderate to 
Severe Localized Scleroderma (Morphea) 
Protocol Number: 
FI-SC-001 
Sponsor: 
Fibrocell Technologies, Inc. 
405 Eagleview Boulevard 
Exton, PA 19341 
Investigational Product: 
FCX-013 
Protocol Version/Date: 
Version 2.0, 10 August 2020 
 
 
GCP Statement 
This study will be conducted in accordance with the United States (US/USA) Food and Drug 
Administration (FDA) and International Conference on Harmonization (ICH) guidelines on 
current Good Clinical Practice (GCP) in accordance with the ethical principles that have their 
origin in the Declaration of Helsinki, and relevant country-specific regulatory requirements  of 
the country in which the research will be conducted. 
 

Protocol FI-SC-001 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
 
Confidential 
 
Page 2 of 57 
1. 
SIGNATURES 
 
Title: 
A Phase 1/2 Study of a Combination of FCX-013 (Genetically-
Modified Autologous Human Dermal Fibroblasts) plus Veledimex 
for the Treatment of Moderate to Severe Localized Scleroderma 
(Morphea) 
Protocol Number: 
FI-SC-001 
Sponsor: 
Fibrocell Technologies, Inc. 
405 Eagleview Boulevard 
Exton, PA 19341 
Investigational Product: 
FCX-013 
Protocol Version / Date: 
Version 2.0, 10 August 2020 
 
Sponsor’s Approval 
The protocol has been approved by Fibrocell Technologies, Inc. (Fibrocell). 
 
Sponsor’s Authorized Officer: 
 
 
 
Mary Spellman, MD 
Chief Medical Officer 
 
 
Date 
 
 
 

Protocol FI-SC-001 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
 
Confidential 
 
Page 3 of 57 
Investigator’s Agreement 
Title: 
A Phase 1/2 Study of a Combination of FCX-013 (Genetically-
Modified Autologous Human Dermal Fibroblasts) plus Veledimex 
for the Treatment of Moderate to Severe Localized Scleroderma 
(Morphea) 
Protocol Number: 
FI-SC-001 
Sponsor: 
Fibrocell Technologies, Inc. 
405 Eagleview Boulevard 
Exton, PA 19341 
Investigational Product: 
FCX-013 
Protocol Version / Date: 
Version 2.0, 10 August 2020 
I have read and understood the contents of the protocol FI-SC-001. 
• I agree that the Protocol contains all of the information necessary to conduct the 
study. 
• I agree to conduct the study as outlined herein and in accordance with ICH guidelines 
on current GCP, with applicable US FDA regulations set forth in 21 CFR parts 50, 
54, and 312, and all other relevant country-specific regulatory requirements of the 
country in which the research will be conducted. 
• I acknowledge that I am responsible for overall study conduct. I agree to personally 
conduct or supervise the described study. 
• I agree to ensure that all associates, colleagues, and employees assisting in the 
conduct of the study are informed about their obligation and comply with the study 
protocol. 
I agree to maintain the confidentiality of all information received or developed in connection 
with this protocol. 
 
  _____________________________ 
Principal Investigator’s Name (Printed) 
 
_____________________________     ________ 
 
 
Principal Investigator’s Signature         Date 
 
 
 
 
 
 

Protocol FI-SC-001 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
 
Confidential 
 
Page 4 of 57 
2. 
SYNOPSIS 
Name of Sponsor/Company: 
Fibrocell Technologies, Inc. (Fibrocell) 
Name of Investigational Product: 
FCX-013 + veledimex (FCX-013 plus veledimex) 
Name of Active Ingredient: 
FCX-013 (Genetically Modified Autologous Human Dermal Fibroblasts) 
Veledimex capsules for oral administration 
Protocol Number: FI-SC-001 
Phase: 1/2 
Country: USA 
Title of Study:  
A Phase 1/2 Study of a Combination of FCX-013 (Genetically-Modified Autologous Human 
Dermal Fibroblasts) Plus Veledimex for the Treatment of Moderate to Severe Localized 
Scleroderma (Morphea) 
Study center(s):  Up to 3 centers 
Studied period (years):  
Estimated date first subject screened: 4Q2019 
Estimated date last subject completed: 2035 (includes 
long-term follow-up) 
Phase of development: I 
Phase 1/2  
Objectives:  
Primary: 
The primary objective of this protocol is to evaluate the safety of FCX-013 plus veledimex in 
subjects with moderate to severe localized scleroderma/morphea. 
Secondary: 
The secondary objective of this protocol is to evaluate the antifibrotic effects of FCX-013 
plus veledimex via the LoSCAT (Localized Scleroderma Assessment Tool) and durometry. 
Methodology:  
This is an open-label, single arm Phase 1/2 study being conducted by Fibrocell to evaluate 
FCX-013 in subjects with moderate to severe localized scleroderma. Approximately ten 
subjects will be enrolled and receive FCX-013. 
The study is divided into the following periods: Screening (including Manufacturing of FCX-
013), Treatment, and Long-Term Follow-Up. The Screening Period consists of evaluation of 
eligibility, the collection of one set of three 3-4 mm biopsies for the manufacture of FCX-013 
product, and the identification of potential target sclerotic lesions. Due to the FCX-013 
manufacturing process, the Screening Period is expected to have a duration of approximately 
4-6 months; however, this period can be extended to accommodate subject scheduling, 
variations in manufacturing duration and protocol mandated delays (i.e. pauses due to 
staggered treatment). 

Protocol FI-SC-001 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
 
Confidential 
 
Page 5 of 57 
After FCX-013 manufacturing is complete, Fibrocell (the Sponsor) and the Investigator will 
mutually agree on the planned date for injection of FCX-013. 
The Treatment Period will have a 2-week duration. One administration of FCX-013 will 
consist of a maximum of 4 mL of FCX-013 administered in up to sixteen (16) 0.25 mL 
intradermal injections. On Day 1, FCX-013 will be intradermally injected, using a retro-
tracing technique, into the sclerotic lesion targeted for treatment. On Day 1, following the 
injection of FCX-013, subjects will initiate a 14-day course of veledimex to be taken orally 
daily. 
Administering FCX-013 following each of the first three subjects requires that the previous 
subject complete Week 4 evaluations, and that the Investigator(s) must have received 
approval from the Data Safety Monitoring Board (DSMB). 
The End of Treatment visit is at Week 12. 
Safety and clinical efficacy evaluations are conducted throughout the study. Safety will be 
assessed through adverse events (AEs), physical examinations, vital signs, clinical laboratory 
evaluations, electrocardiograms (ECGs) and concomitant medications. 
The Long-Term Follow-Up period is an approximately 15-year period following the End of 
Treatment in which safety is monitored annually. 
Number of subjects (planned):  
Approximately 10 
Diagnosis and main criteria for inclusion:  
Adults with a clinical diagnosis of any subtype of moderate to severe localized 
scleroderma/morphea with sclerotic lesions. 
Investigational product, dosage and mode of administration: 
• 
FCX-013 via intradermal injection 
• 
Veledimex capsule for oral administration 
One administration of FCX-013 will consist of a maximum of 4 mL of FCX-013 
administered in up to sixteen (16) 0.25 mL intradermal injections. On Day 1, FCX-013 will 
be intradermally injected, using a retro-tracing technique, into the sclerotic lesion targeted for 
treatment. On Day 1, following the injection of FCX-013, subjects will initiate a 14-day 
course of veledimex to be taken orally daily. 
Reference therapy, dosage and mode of administration:  
Not applicable. 
Criteria for evaluation: 
Safety:  Safety will be assessed through AEs, physical examinations, vital signs, clinical 
laboratory evaluations, ECGs, and concomitant medication use. Analysis of replication-
competent lentivirus (RCL) antibodies will also be performed. 
Efficacy:  Clinical evaluation of antifibrotic effects via durometry evaluation and LoSCAT 
(Localized Scleroderma Assessment Tool). 

Protocol FI-SC-001 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
 
Confidential 
 
Page 6 of 57 
Quality of life will be assessed using the SkinDex 29+3. 
Statistical methods: 
Descriptive statistics are planned for this study. 
Safety: 
Safety evaluations will be based on listed AEs, physical examinations, vital signs, clinical 
laboratory evaluations, ECGs and prior/concomitant medications, and assessment for the 
presence of  RCL antibodies. The AE severity will be described using National Cancer 
Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grades, using 
the current version at study start. AEs will be coded using the Medical Dictionary for 
Regulatory Activities (MedDRA; version 23.0 or later) and described by body system and 
preferred term, relationship to FCX-013, seriousness, and severity. AEs causing 
investigational product discontinuation and/or early study discontinuation, and serious 
adverse events (SAEs) will be noted. 
Efficacy: 
All subjects who were administered FCX-013 and had at least one assessment of the target 
lesion post-administration will be included in the efficacy population. 
The change from baseline in the LoSCAT and durometry scores will be reported 
descriptively, as will changes in the SkinDex 29+3 scores. 
The primary method of handling data will be last observation carried forward (LOCF). 
 
 

Protocol FI-SC-001 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
 
Confidential 
 
Page 7 of 57 
3. 
TABLE OF CONTENTS 
1. 
SIGNATURES .............................................................................................................2 
2. 
SYNOPSIS ...................................................................................................................4 
3. 
TABLE OF CONTENTS .............................................................................................7 
4. 
LIST OF ABBREVIATIONS.....................................................................................11 
5. 
INTRODUCTION ......................................................................................................12 
5.1. 
Background: Localized Scleroderma/Morphea ..........................................................12 
5.2. 
Study Rationale ...........................................................................................................13 
6. 
TRIAL OBJECTIVES AND ENDPOINTS ...............................................................14 
7. 
INVESTIGATIONAL PLAN .....................................................................................15 
7.1. 
Overall Study Design ..................................................................................................15 
7.2. 
Number of Subjects ....................................................................................................15 
7.3. 
Treatment Assignment ................................................................................................15 
7.4. 
Randomization and Blinding ......................................................................................16 
7.5. 
Dose Adjustment Criteria ...........................................................................................16 
7.5.1. 
Safety Criteria for Adjustment or Stopping Doses .....................................................16 
7.5.2. 
Early Cessation of Study Treatment for an Individual ...............................................17 
7.6. 
Study Termination ......................................................................................................17 
7.7. 
Safety Oversight: Data Safety Monitoring Board ......................................................17 
8. 
SELECTION AND WITHDRAWAL OF SUBJECTS ..............................................19 
8.1. 
Subject Inclusion Criteria ...........................................................................................19 
8.2. 
Subject Exclusion Criteria ..........................................................................................20 
8.3. 
Subject Withdrawal Criteria .......................................................................................21 
9. 
TREATMENT OF SUBJECTS ..................................................................................23 
9.1. 
Description of Investigational Products ......................................................................23 
9.2. 
Investigational Product Dosing ...................................................................................23 
9.3. 
Lesion Selection Criteria/Guidelines ..........................................................................24 
9.4. 
Prior and Concomitant Medications ...........................................................................24 
9.5. 
Contraception ..............................................................................................................26 
10. 
STUDY ASSESSMENTS AND PROCEDURES ......................................................27 
10.1. 
Schedule of Study Visits and Assessments ................................................................27 
10.2. 
Study Procedures by Visit ..........................................................................................30 

Protocol FI-SC-001 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
 
Confidential 
 
Page 8 of 57 
10.2.1. 
Prescreening and Screening (Visit 1) .........................................................................30 
10.2.2. 
Baseline (Day 1) .........................................................................................................30 
10.2.3. 
Week 2 (Day 15) / Week 4 (Day 29) ..........................................................................31 
10.2.4. 
Week 12/End of Treatment .........................................................................................31 
10.2.5. 
Long-Term Follow-Up ...............................................................................................31 
10.2.6. 
Unscheduled Visit .......................................................................................................31 
10.3. 
Assessments ................................................................................................................31 
10.3.1. 
Demographics .............................................................................................................31 
10.3.2. 
Medical/Surgical History, Prior and Concomitant Medications .................................31 
10.3.3. 
Vital Signs ..................................................................................................................32 
10.3.4. 
Physical Examination .................................................................................................32 
10.3.5. 
Electrocardiogram .......................................................................................................32 
10.3.6. 
Skin Biopsy for FCX-013 Manufacturing ..................................................................33 
10.3.7. 
Laboratory Assessments: Hematology and Blood Chemistry ....................................33 
10.3.8. 
Replication Competent Lentivirus Analysis ...............................................................34 
10.3.9. 
Durometry ...................................................................................................................34 
10.3.10. 
LoSCAT ......................................................................................................................35 
10.3.11. 
SkinDex ......................................................................................................................35 
11. 
STUDY DRUG MATERIALS AND MANAGEMENT ...........................................36 
11.1. 
Study Drug Materials and Administration ..................................................................36 
11.1.1. 
FCX-013 .....................................................................................................................36 
11.1.2. 
Veledimex ...................................................................................................................37 
11.2. 
Study Drug Accountability .........................................................................................38 
11.3. 
Study Drug Handling and Disposal ............................................................................38 
12. 
ADVERSE EVENTS..................................................................................................39 
12.1. 
Adverse Event Definitions ..........................................................................................39 
12.1.1. 
Serious Adverse Event ................................................................................................40 
12.2. 
Reporting Procedure ...................................................................................................41 
12.2.1. 
SAE Reporting Procedure ...........................................................................................41 
12.2.2. 
Follow-Up of Adverse Events ....................................................................................42 
12.2.3. 
Relationship of Adverse Event to Investigational Product .........................................42 
12.2.4. 
Severity of Adverse Event ..........................................................................................43 

Protocol FI-SC-001 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
 
Confidential 
 
Page 9 of 57 
12.3. 
Pregnancy ...................................................................................................................43 
13. 
STATISTICS ..............................................................................................................44 
13.1. 
Sample Size Determination ........................................................................................44 
13.2. 
Analysis Populations ..................................................................................................44 
13.3. 
Demographic and Baseline Characteristics ................................................................44 
13.4. 
Safety Analyses ..........................................................................................................45 
13.5. 
Efficacy Analyses .......................................................................................................45 
13.6. 
Interim Analysis ..........................................................................................................45 
13.7. 
Handling of Missing and Incomplete Data .................................................................45 
14. 
ETHICS AND GENERAL STUDY CONDUCT CONSIDERATIONS ...................46 
14.1. 
Ethical Conduct of the Study ......................................................................................46 
14.2. 
Institutional Review Board .........................................................................................46 
14.3. 
Subject Information and Consent ...............................................................................47 
14.3.1. 
General Provisions ......................................................................................................47 
14.4. 
Protocol Compliance ..................................................................................................47 
14.5. 
Changes to the Protocol ..............................................................................................48 
14.6. 
Posting of Information on Publicly Available Clinical Trial Registers ......................48 
14.7. 
Study Documentation .................................................................................................48 
14.7.1. 
Investigator Study File ................................................................................................48 
14.7.1.1. 
Subject’s Source Documentation ................................................................................48 
14.7.1.2. 
Pre-Study Documentation Requirements ...................................................................49 
14.8. 
Data Collection, Management, Monitoring, and Retention ........................................49 
14.8.1. 
Data Collection and Management ..............................................................................49 
14.8.1.1. 
Subject Confidentiality ...............................................................................................50 
14.8.1.2. 
Data Quality Control and Reporting ...........................................................................50 
14.8.1.3. 
Monitoring/Auditing ...................................................................................................51 
14.8.1.4. 
Retention of Records ..................................................................................................51 
14.9. 
Future Use of Stored Specimens and Data .................................................................51 
14.10. 
Publication Policy .......................................................................................................52 
15. 
REFERENCES ...........................................................................................................53 
APPENDIX 1. BIOSPY COLLECTION PROCEDURES .........................................................54 

Protocol FI-SC-001 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
 
Confidential 
 
Page 10 of 57 
APPENDIX 2. INVESTIGATIONAL PRODUCT ADMINISTRATION 
INSTRUCTIONS .......................................................................................................55 
APPENDIX 3. LOCAL SCLERODERMA CUTANEOUS ASSESSMENT TOOL 
(LOSCAT) ..................................................................................................................56 
APPENDIX 4. PATIENT REPORTED OUTCOME: SKINDEX 29+3 ....................................57 
 
LIST OF TABLES 
Table 1: 
Investigational Product ...............................................................................................23 
Table 2: 
FCX-013 Cell Count, Vial and Injections per Treatment Session ..............................23 
Table 3: 
Medicine Classes that may Affect CYP450 3A4 .......................................................25 
Table 4: 
Schedule of Events .....................................................................................................28 
Table 5: 
FCX-013 Cell Count and Injections per Administration ............................................37 
Table 6: 
Criteria for Determining the Grade/Severity of Adverse Event Terms Not 
Specified by the NCI CTCAE Criteria .......................................................................43 
 
 

Protocol FI-SC-001 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
 
Confidential 
 
Page 11 of 57 
4. 
LIST OF ABBREVIATIONS 
Abbreviation 
Definition 
AE 
Adverse Event 
ALT/SGPT 
Alanine Aminotransferase 
AST/SGOT 
Aspartate Aminotransferase 
CFR 
Code of Federal Regulations 
CRF 
Case Report Form 
CTCAE 
Common Terminology Criteria for Adverse Events 
DSMB 
Data Safety Monitoring Board 
ECG 
Electrocardiogram 
EDC 
Electronic Data Capture 
FAS 
Full Analysis Set 
FCX-013 
Genetically-Modified Autologous Human Dermal Fibroblasts  
(product -013) 
FDA 
Food and Drug Administration 
GCP 
Good Clinical Practice 
Hep B 
Hepatitis B 
Hep C 
Hepatitis C  
HIPAA 
Health Insurance Portability and Accountability Act 
HIV 
Human Immunodeficiency Virus 
IB 
Investigator’s Brochure 
ICF 
Informed Consent Form 
ICH 
International Conference on Harmonization 
IP 
Investigational Product 
IRB 
Institutional Review Board 
LOCF 
Last Observation Carried Forward 
MCH/MCHC/
MCV 
Mean Corpuscular Hemoglobin/ Hemoglobin Concentration/Volume 
MedDRA 
Medical Dictionary for Regulatory Activities 
MMP 
Matrix Metalloproteinase 
NCI 
National Cancer Institute 
PCR 
Polymerase Chain Reaction 
PI 
Principal Investigator 
PP 
Per Protocol 
qPCR 
Quantitative Polymerase Chain Reaction 
RBC 
Red Blood Cell(s) 
RCL 
Replication-Competent Lentivirus 
RDW 
Red Cell Distribution Width 
SAE 
Serious Adverse Event 
Sub-I 
Sub-Investigator 
TEAE 
Treatment-Emergent Adverse Events 
US/USA 
United States of America 
WBC 
White Blood Cell(s) 
WHODrug 
World Health Organization Drug Global Dictionary 

Protocol FI-SC-001 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
 
Confidential 
 
Page 12 of 57 
5. 
INTRODUCTION 
5.1. 
Background: Localized Scleroderma/Morphea 
Localized scleroderma/morphea is an autoimmune inflammatory sclerosing disorder of 
cutaneous induration that can cause permanent functional disability and disfigurement. This rare 
fibrosing disorder of the skin and underlying tissues is distinct from systemic sclerosis and 
encompasses several subtypes classified by the depth and pattern of lesion(s). The underlying 
pathogenesis of localized scleroderma is not completely understood but is likely multifactorial, 
involving genetic factors and environmental exposures, culminating in small vessel damage, 
release of profibrotic cytokines, and ultimately leading to disruption of the balance between 
collagen synthesis and destruction. The incidence and prevalence of localized scleroderma is 
poorly described. The incidence of localized scleroderma has been estimated as approximately 
0.4 to 2.7 per 100,000 individuals. (Fett, 2011 Part 1; Peterson, 1997). Prevalence of localized 
scleroderma is approximately 50 per 100,000 individuals (Browning, 2013). The prevalence is 
similar in children and adults (Peterson, 1997, Leitenberger, 2009). 
Overproduction and accumulation of collagen is a hallmark of the disease. Given the increased 
levels of collagen, a biological approach to break down and inhibit collagen synthesis by a 
matrix metalloproteinase (MMP) is a novel therapeutic approach for the treatment of localized 
scleroderma. 
The assessment of disease activity and depth of involvement guides therapeutic decision-making 
in localized scleroderma/morphea. Because of the self-limited nature of localized 
scleroderma/morphea, patients with limited plaque disease may elect to defer therapy. For 
patients with superficial (dermal) circumscribed disease who desire treatment, but do not have 
access to or prefer to avoid the frequent visits required for phototherapy, treatment options 
include high potency topical corticosteroids, intralesional corticosteroids, a topical vitamin D 
analog, topical tacrolimus, or imiquimod. For patients with superficial (dermal) forms of 
morphea who are able to receive phototherapy, treatment with UVA1 is preferred; alternatives 
include broad-band UVA, narrow-band UVB, or PUVA. Phototherapy is unlikely to be effective 
for localized scleroderma/morphea involving the subcutaneous tissue, muscle, or bone. Rapidly 
progressive, severe, disabling disease requires systemic therapy, involving a combination of 
methotrexate and systemic corticosteroids. Localized scleroderma/morphea may cause joint 
contractures and other functional impairments secondary to deep tissue sclerosis. All patients 
should be clinically assessed for the development of these findings. Physical therapy is essential 
for patients at risk for or who show evidence of functional impairments. 
The risk-benefit assessment of pursuing treatment for localized scleroderma lesions depends on 
the potential for functional impairment and symptom burden due to sclerotic lesions. 

Protocol FI-SC-001 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
 
Confidential 
 
Page 13 of 57 
5.2. 
Study Rationale 
Fibrocell is developing a two-component therapeutic consisting of FCX-013 and veledimex for 
the treatment of localized scleroderma (morphea) by resolving fibrotic lesions and normalizing 
dermal collagen production. The first component, FCX-013, is genetically-modified autologous 
human dermal fibroblasts that have been engineered with a lentiviral vector to express MMP-1 
under the control of a RheoSwitch (RTS®) system. The lentiviral vector-containing gene 
constructs for MMP-1 and the RTS® is referred to as LV-RTS-MMP-1 (or INXN-2005). The 
second component, veledimex, is a small molecule which activates the RTS to induce expression 
of MMP-1. The FCX-013 product is administered by intradermal injection, and veledimex is 
administered orally in a liquid filled gelatin capsule formulation. 
The clinical trial will be conducted in compliance with the protocol, Good Clinical Practice 
(GCP), and applicable regulatory requirements. 

Protocol FI-SC-001 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
 
Confidential 
 
Page 14 of 57 
6. 
TRIAL OBJECTIVES AND ENDPOINTS 
Primary Objective 
The primary objective of this study is to evaluate the safety of FCX-013 plus veledimex in 
subjects with moderate to severe localized scleroderma/morphea. 
Secondary Objective 
The secondary objective of this study is to evaluate the antifibrotic effects of FCX-013 plus 
veledimex via durometry and the LoSCAT (Localized Scleroderma Assessment Tool). 
Safety evaluations include assessment of treatment-emergent adverse events (TEAEs), 
including serious adverse events (SAEs); change in clinical laboratory values; change in vital 
signs; change in electrocardiograms (ECGs); and incidence of replication-competent lentivirus 
(RCL) antibodies. 
Efficacy endpoints include the change from Baseline in the durometer score and LoSCAT score. 

Protocol FI-SC-001 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
 
Confidential 
 
Page 15 of 57 
7. 
INVESTIGATIONAL PLAN 
7.1. 
Overall Study Design 
This is an open-label, single arm Phase 1/2 study being conducted by Fibrocell to evaluate FCX-
013 in subjects with moderate to severe localized scleroderma/morphea. Approximately ten 
subjects will be enrolled and receive FCX-013. 
The study is divided into the following periods: Screening (including Manufacture), Treatment, 
and Long-Term Follow-Up. The Screening Period consists of entry criteria evaluations, the 
collection of one set of three 3-4 mm biopsies for the manufacture of FCX-013 product, and the 
identification of potential target sclerotic lesions. Due to the FCX-013 manufacturing process, 
the Screening Period is expected to have a duration of approximately 4-6 months; however, this 
period can be extended to accommodate subject scheduling, variations in manufacturing duration 
and protocol mandated delays (i.e. pauses due to staggered treatment). 
After FCX-013 manufacturing is complete, Fibrocell (the Sponsor) and the Investigator will 
mutually agree on the planned date for injection of FCX-013. 
The Treatment Period will have a 12-week duration. One administration of FCX-013 will consist 
of a maximum of 4 mL of FCX-013 administered in up to sixteen (16) 0.25 mL intradermal 
injections. On Day 1, FCX-013 will be intradermally injected, using a retro-tracing technique, 
into the sclerotic lesion targeted for treatment. On Day 1, following the injection of FCX-013, 
subjects will initiate a 14-day course of veledimex to be taken orally daily. During the Treatment 
Period, subjects will be evaluated at Weeks 2, 4, and 12, and have an end-of-treatment visit at 
Week 12. 
Treatment with FCX-013 will be staggered for the first three subjects. Administering FCX-013 
following each of the first three subjects requires that the previous subject complete Week 4 
evaluations, and that the Investigator(s) must have received approval from the Data Safety 
Monitoring Board (DSMB).  
Safety and clinical efficacy evaluations are conducted throughout the study. Safety will be 
assessed through adverse events (AEs), physical examinations, vital signs, clinical laboratory 
evaluations, ECGs and concomitant medications.  
The Long-Term Follow-Up period is an approximately 15-year period following End of 
Treatment in which an examination of injection sites is conducted, and safety is monitored 
annually, at a minimum. 
7.2. 
Number of Subjects 
The enrollment target is approximately 10 subjects. 
7.3. 
Treatment Assignment 
This is an open label study. All subjects will receive a combination of FCX-013 plus veledimex. 
Upon screening, the subject will be assigned a unique Subject Number. Subjects who are eligible 
for participation will retain the same Subject Number for the duration of the study. Subjects who 

Protocol FI-SC-001 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
 
Confidential 
 
Page 16 of 57 
satisfy all the inclusion and none of the exclusion criteria will enter a screening period prior to 
injection(s) with FCX-013 and veledimex administration. 
7.4. 
Randomization and Blinding 
This is an open-label, single-arm study. No randomization or blinding techniques will be utilized. 
7.5. 
Dose Adjustment Criteria 
7.5.1. 
Safety Criteria for Adjustment or Stopping Doses 
An objective of this study is to generate a safety profile of FCX-013 plus veledimex in subjects 
with moderate to severe localized scleroderma/morphea. To minimize risk, cumulative safety 
data will be reviewed by the Medical Monitor. Events that will result in immediate enrollment 
discontinuation and treatment discontinuation for all subjects are a positive RCL assay and 
histologically confirmed cancer in combination with the presence of viral vector in the tumor. In 
addition, the Medical Monitor may interrupt study dosing and/or study entry at any time if 
medically indicated.  
Occurrence of any of these observations will trigger a temporary suspension of FCX-013 plus 
veledimex administration pending a safety investigation: 
• A treatment emergent SAE or suspected SAE related to FCX- 013, the FCX-013 
administration procedure, veledimex administration or any other protocol procedure. 
• A positive RCL quantitative polymerase chain reaction (qPCR) assay result. A positive 
RCL qPCR assay will result in suspension of FCX-013 administration. The result will be 
confirmed by conducting a biological-based assay. If both assays are positive, FCX-013 
administration will be discontinued and no further enrollment into the study will be 
allowed. 
• An autoimmune response determined by the Investigator to be possibly, probably or 
definitely related to treatment. 
• Any systemic infection designated as suspected to be related to FCX-013. 
• A treatment emergent uncontrolled bacterial, viral, or fungal infection in a lesion that was 
administered by investigational product (IP) where product sterility testing results 
reported post injection were positive for contamination. 
• Any subject diagnosed with a histologically proven skin cancer (including sarcomas) will 
be biopsied and assayed for viral vector by qPCR. A positive result for viral vector will 
cause product administration to be suspended. 
• Abnormal laboratory value(s) or clinically significant change from screening/baseline 
that pose a risk to safe participation.  
• Abnormal test procedure result(s) or clinically significant change from screening/baseline 
that pose a risk to safe participation (e.g., Grade 2 or above Common Terminology Criteria 
for Adverse Events/CTCAE criteria (v.4.03) for ECG test). 

Protocol FI-SC-001 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
 
Confidential 
 
Page 17 of 57 
For subject safety, investigators should continue to follow subjects in accordance with study 
visits and procedures as outlined in the protocol. An occurrence of any of these safety 
observations will be shared with all study Investigators, DSMB and the appropriate regulatory 
authorities. The DSMB will review the results of the safety investigation and may request any 
additional data needed to assess the safety of restarting product administration. The DSMB will 
determine if the suspension can be lifted or if the trial will need to terminate based on their 
review of the safety investigation. 
7.5.2. 
Early Cessation of Study Treatment for an Individual 
Subjects may voluntarily stop receiving treatment at any time. 
Unless a subject withdraws consent, subjects who voluntarily cease to receive treatment will 
continue to be followed as per the trial protocol and clinical assessment schedule to ensure that 
full data are obtained. 
The Primary Investigator and/or the Sponsor may decide that early cessation of treatment is 
warranted for any one of the following reasons: 
• Occurrence of AEs that pose a risk to safe participation 
• Abnormal laboratory value(s) that pose a risk to safe participation 
• Abnormal test procedure result(s) that pose a risk to safe participation 
• Unsatisfactory therapeutic effect 
• Condition no longer requires treatment 
• Pregnancy 
Subjects can withdraw from the study for any reason including worsening disease and to receive 
rescue therapy/standard-of-care treatment for worsening disease. 
For subjects who are lost to follow-up, the Investigator should show due diligence by 
documenting in the source documents the steps taken to contact the subject (e.g., dates of 
telephone calls, emails). 
7.6. 
Study Termination 
Fibrocell reserves the right to terminate the study, according to the study contract. The 
investigator should notify the Institutional Review Board (IRB) in writing of the trial’s 
completion or early termination and send a copy of the notification to Fibrocell. 
7.7. 
Safety Oversight: Data Safety Monitoring Board 
A DSMB will be comprised of two clinicians with expertise in dermatology and/or scleroderma, 
and a statistician. The DSMB will facilitate the management and identification of potential safety 
concerns that could affect the safety of study subjects and will evaluate the overall progress of 
the study through the Treatment Period. To minimize risk, cumulative safety data will be 
reviewed by the DSMB. Principal investigators (PIs), additional sub-investigators (Sub-Is) and 
scientific personnel may participate in reviews, as appropriate. 

Protocol FI-SC-001 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
 
Confidential 
 
Page 18 of 57 
The DSMB has the authority to recommend dose or regimen modifications for safety concerns 
and will provide recommendations about stopping or continuing the trial. To contribute to 
enhancing the integrity of the trial, the DSMB may also formulate recommendations relating to 
the selection/recruitment/retention of subjects, their management, improving adherence to 
protocol-specified regimens and retention of subjects, and the procedures for data management 
and quality control. 
Details regarding the DSMB, procedures, responsibilities, membership, meeting intervals and 
data to be evaluated will be further described in the study specific DSMB Charter. A written 
summary documenting the results and recommendations of each DSMB meeting will be 
maintained on file with the Sponsor. 

Protocol FI-SC-001 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
 
Confidential 
 
Page 19 of 57 
8. 
SELECTION AND WITHDRAWAL OF SUBJECTS 
Approximately 10 adult subjects with localized scleroderma/morphea will be enrolled in the 
study at approximately 2 investigative sites in the US. 
Subjects must meet all of the inclusion criteria and none of the exclusion criteria at Screening 
and Day 1 to be considered eligible for participation in this study. 
Protocol violations from inclusion and exclusion criteria are prohibited because ineligible study 
subjects can potentially jeopardize the scientific integrity of the study, regulatory acceptability, 
or subject safety. 
8.1. 
Subject Inclusion Criteria 
A subject must meet all of the following criteria to be eligible for treatment in this study: 
1. Subject is an adult, ≥ 18 years of age at Screening, with moderate to severe localized 
scleroderma/morphea with sclerotic lesions which have been unresponsive to standard of 
care therapy. 
2. Subject has stable control of localized disease (clinically inactive) over the 3 months 
prior to Screening and through Baseline (Day 1).  
3. Subject has not participated in previous clinical research study in the 3 months prior to 
Screening and through Baseline (Day 1). 
4. Subject has provided informed written consent. 
5. Female subjects of childbearing potential and male subjects engaging in sexual activity 
that could lead to pregnancy agree to use of at least one of the following adequate birth 
control regimens while in the study and for 3 months after study medication (FCX-013 or 
veledimex) is administered: 
• Male partner with vasectomy 
• Male condom AND partner use of one of the contraceptive options below: 
− Spermicide  
− Intrauterine device or intrauterine system 
− Oral contraceptive, either combined or progestogen alone 
− Contraceptive subdermal implant (e.g., Norplant®) 
− Injectable progestogen (e.g., Depo-Provera®) 
− Contraceptive vaginal ring (e.g., NuvaRing®) 
− Transdermal contraceptive patches (e.g., Ortho Evra®) 
• Subjects of childbearing potential who are abstinent agree to use one of the birth 
control regimens listed if they initiate sexual activity that could lead to pregnancy 
during the study. 

Protocol FI-SC-001 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
 
Confidential 
 
Page 20 of 57 
Periodic abstinence e.g., calendar, ovulation, sympto-thermal, post-ovulation methods 
and withdrawal are not acceptable methods of contraception.  
Non-childbearing potential females are defined as females who are premenarchal, or 
postmenopausal (12 months with no menstrual period without an alternative medical 
cause), or who have undergone a hysterectomy, bilateral tubal ligation, bilateral 
oophorectomy (removal of the ovaries), or hysteroscopic sterilization. Documented 
verbal history from the subject is acceptable. 
6. Subject is, in the opinion of the Investigator, able to understand the study, cooperate with 
the study procedures and willing to return to the clinic for the required follow-up visits. 
8.2. 
Subject Exclusion Criteria 
A subject who meets any of the following criteria will be excluded and considered ineligible for 
participation in the study: 
1. Subject has a clinically significant skin disorder other than localized 
scleroderma/morphea in the anatomical area (e.g., same arm, same side of abdomen) of 
interest. 
2. Subject has localized scleroderma/morphea with potential target lesions only located on 
the face or over a joint, or lesions that can be successfully managed with topical 
medications or phototherapy. 
3. Subject has symptoms consistent with systemic scleroderma that have not been stable, or 
that require treatment that has not been stable for 3 months prior to Screening and 
through Baseline (Day 1). 
4. Subject has been treated with UVA1 phototherapy within 2 months prior to Baseline 
(Day 1).  
5. Subject requires treatment with a non-stable regimen of systemic immunosuppressive 
therapy, for any medical condition, or plans to initiate such treatment during the study 
period.  
6. Subject requires treatment with a non-stable regimen of physical therapy, for localized 
scleroderma/morphea, or plans to initiate such treatment during the study period.  
7. Subject has any medical instability limiting ability to travel to the investigative center. 
8. Subject has clinical signs of infection at (or in close proximity to) the target lesion. 
9. Subject has a history of, or current, malignancy at/near site of injection (except basal cell 
carcinoma or squamous cell carcinoma that have been treated). 
10. Subject has a history of, or current, clinically significant liver abnormalities.  
11. Subject has a history of, or current, clinically significant cardiac abnormalities, or a 
significant abnormality on ECG, including a QT interval corrected for heart rate 
(Fridericia; QTcF interval) of > 450 milliseconds in males and > 470 milliseconds in 
females.  

Protocol FI-SC-001 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
 
Confidential 
 
Page 21 of 57 
12. Subject has clinically significant laboratory abnormalities which may affect their ability 
to safety participate in the study. 
13. Subject has active infection with human immunodeficiency virus (HIV) as determined by 
HIV screening, or hepatitis B (hep B) or hepatitis C (hep C), as determined by hep B 
surface antigen screening, detection of hep C antibodies, or positive result of hep C 
polymerase chain reaction (PCR) analysis.  
14. Subject has an active drug or alcohol addiction. 
15. Subject has any known allergy to any of the constituents of the product. 
16. Subject has received an interventional chemical or biological investigational study 
product for the specific treatment of localized scleroderma in the 3 months prior to 
Screening and through Baseline (Day 1). 
17. Subject is pregnant or nursing or plans to become pregnant or nurse during the study 
period. 
8.3. 
Subject Withdrawal Criteria 
A subject is free to withdraw from the study at any time for any reason without prejudice to their 
future medical care by the physician or at the institution. The Investigator or Sponsor may also 
withdraw the subject at any time in the interest of subject safety or for other reasons. Criteria for 
withdrawal include:  
• Consent is withdrawn  
• The subject refuses treatment and/or procedures/observations 
• Occurrence of unmanageable AEs, or pregnancy 
• For other reasons (e.g., significant protocol violation, non-compliance) 
The Sponsor may be contacted if clarification is required. 
The primary reason for withdrawal must be recorded on the case report form (CRF). Comments 
or complaints regarding the withdrawal made by the subject must also be recorded on the CRF. 
Withdrawal information will be communicated to the DSMB at each meeting. Withdrawal 
should be discussed with the medical monitor prior to withdrawal when possible. Subjects who 
wish to discontinue treatment or study procedures after receipt of FCX-013 will be asked to 
continue in the Long-Term Follow-Up Period.  
Subjects who withdraw prior to FCX-013 administration will be considered a screen failure and 
will be replaced. The Sponsor reserves the right to terminate the study.  
Discontinuation of FCX-013 administration does not mean discontinuation from the study. The 
study assessments and procedures for the visit and subsequent visits should be completed as 
indicated in the Schedule of Events (Table 4) and reason for discontinuation of FCX-013 
administration should be documented in the subject’s source documents and CRF. 
If a subject discontinues from the study, every effort must be made to perform the study 
assessments and procedures specified for an Early Termination Visit (Week 12). The primary 

Protocol FI-SC-001 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
 
Confidential 
 
Page 22 of 57 
reason for subject’s withdrawal from the study should be documented in the subject’s source 
documents and CRF. 
Subjects who discontinue from the study following IP administration will be asked to participate 
in the Long-Term Safety Follow-up period. 

Protocol FI-SC-001 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
 
Confidential 
 
Page 23 of 57 
9. 
TREATMENT OF SUBJECTS 
9.1. 
Description of Investigational Products 
Table 1: 
Investigational Product 
 
Investigational Product 
Product Name 
 FCX-013 
Veledimex 
Dosage Form 
Cell suspension 
Capsule 
Unit Dose 
2 mL (containing approximately 
1.2 mL of FCX-013) 
40 mg 
Route of Administration 
Intradermal injection 
Oral 
Physical Description 
Opaque liquid 
Liquid filled capsule 
9.2. 
Investigational Product Dosing 
FCX-013 
Subjects will receive intradermal injections of FCX-013 to treatment lesion(s) in a single 
treatment session, on Day 1. 
Table 2 provides details regarding the number of cells, vials and injections per treatment session. 
A treatment session of FCX-013 will consist of a maximum of 4 mL of FCX-013 administered in 
up to sixteen (16) 0.25 mL intradermal injections. The injections will be administered around the 
perimeter of the sclerotic target lesion(s), approximately 1 cm apart. The Investigator will 
attempt to administer the full 4 mL of FCX-013. Additional details of FCX-013 administration 
can be found in Appendix 2. 
Table 2: 
FCX-013 Cell Count, Vial and Injections per Treatment Session 
FCX-013 Cells: 
~100 million 
Concentration of FCX-013 Suspension: 
10 to 30 million cells/mL 
# Vials: 
Up to 5 
Cells per Injection: 
6 million 
Number of Injections: 
Up to 16 (each injection 0.25mL) 
Veledimex 
Veledimex will be administered once daily, starting on Day 1 following FCX-013 injection. The 
veledimex dose is 160 mg daily (4 capsules containing 40 mg veledimex each), for 14 days. 

Protocol FI-SC-001 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
 
Confidential 
 
Page 24 of 57 
Veledimex must be taken with food. Compliance with veledimex administration will be verified 
at the Week 2 visit, based on subject report and capsule count (accountability). 
9.3. 
Lesion Selection Criteria/Guidelines 
Up to three small lesions will be selected for potential treatment from the trunk, breast, forearm, 
armpit, upper or lower extremities. Lesions on the face and over joints will be excluded. 
Sclerotic lesions will be chosen which have not responded to standard of care. An area of 
unaffected skin in the same body area, typically contralateral, will be measured as a control. 
Final lesion selection will occur on Day 1, and the total injection area must be approximately 16 
linear cm. 
9.4. 
Prior and Concomitant Medications 
Subject’s prior and concomitant medications/treatments (including over-the-counter or 
prescription medication, vitamins and/or herbal supplements) and skin care regimen will be 
reviewed and recorded at Screening and reviewed/updated at every visit. Medications/treatments 
used within 30 days prior to Baseline (Day 1) will be reported in the database.  
Any medications/treatments administered to the subject during the study must be recorded 
including all anesthesia medication used during biopsy procedures. Any changes in concomitant 
medication/treatments will also be recorded. If the reason for change is related to an AE, an AE 
must be recorded.  
Throughout the study, any concomitant medications/treatments deemed necessary to provide 
adequate supportive care may be prescribed. In particular, medication should be considered 
during and after the FCX-013 injections to treat pain and/or anxiety (e.g., lorazepam).  
During long term follow up visits (annually for up to 15 years), concomitant medications should 
also include discussion of exposure to mutagenic agents and other medicinal products to meet 
regulatory guidelines. 
Skin Care Regimen 
There are few restrictions on skin care however, all target wounds should receive same standard 
of care. CBD oil and steroids should not be used at the target lesions. Routine skin care may 
continue throughout the study. 
Prohibited Medications 
The Medical Monitor should be contacted if there are any questions regarding prohibited 
medications/treatments and nondrug therapies. 
The use of the following products is prohibited during this study: 
• Other investigational scleroderma medications/treatments or procedures 
• CBD oil or steroids as skin treatments at the target lesions 
Caution should be used when prescribing medically required medications that are classified as 
CYP450 3A4 inducers, inhibitors, or substrates. See Table 3 for a list of medicine classes that 
may affect CYP450 3A4 and cause potential drug-drug interactions with veledimex. If such 

Protocol FI-SC-001 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
 
Confidential 
 
Page 25 of 57 
medications cannot be avoided or the subject is on stable doses, these subjects should be 
monitored, and doses adjusted accordingly. 
(https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractions
labeling/ ucm093664.htm).  
Table 3: 
Medicine Classes that may Affect CYP450 3A4 
CYP3A Substrates 
CYP3A Inhibitors 
CYP3A inducers 
Macrolide antibiotics: 
Clarithromycin, erythromycin, NOT 
azithromycin, telithromycin 
  
Anti-arrhythmics: 
quinidine→3-OH(not 3A5) 
  
Benzodiazepines: 
Alprazolam, diazepam→3OH, midazolam, 
triazolam 
  
Immune Modulators: 
Cyclosporine, tacrolimus (FK506), sirolimus 
  
HIV Antivirals: 
Indinavir, ritonavir, saquinavir, nevirapine 
  
Prokinetics: 
cisapride 
  
Antihistamines: 
Astemizole, chlorpheniramine 
  
Calcium Channel Blockers: 
Amlodipine, diltiazem, felodipine, Nifedipine, 
nisoldipine, nitrendipine, verapamil 
  
HMG CoA Reductase Inhibitors: 
Atorvastatin, lovastatin, NOT pravastatin, 
NOT rosuvastatin, simvastatin 
 
PDE-5 Inhibitors: 
Sildenafil, tadalafil, vardenafil 
  
Others: 
Alfentanyl, aripiprazole, boceprevir, 
buspirone, carbamazepine, gleevec, 
haloperidol, pimozide, quinine, tamoxifen, 
telaprevir, trazodone, vincristine 
  
HIV Antivirals: 
indinavir 
nelfinavir 
ritonavir 
  
clarithromycin 
itraconazole 
ketoconazole 
nefazodone 
  
erythromycin 
grapefruit juice 
verapamil 
  
suboxone 
diltiazem 
  
cimetidine 
  
amiodarone 
NOT azithromycin 
fluvoxamine 
troleandomycin 
voriconazole 
  
carbamazepine 
efavirenz 
nevirapine 
phenobarbital 
phenytoin 
pioglitazone 
rifabutin 
rifampin 
St. John's Wort 
troglitazone 
 
 

Protocol FI-SC-001 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
 
Confidential 
 
Page 26 of 57 
9.5. 
Contraception 
Female subjects of childbearing potential and fertile male subjects who are engaging in sexual 
activity that could lead to pregnancy must use at least 1 of the following adequate birth control 
regimens while in the study and for 3 months after study medication (FCX-013 or veledimex) is 
administered. 
• Male partner with vasectomy 
• Male condom AND partner use of one of the contraceptive options below: 
− Spermicide 
− Intrauterine device or intrauterine system 
− Oral contraceptive, either combined or progestogen alone 
− Contraceptive subdermal implant (e.g., Norplant®) 
− Injectable progestogen (e.g., Depo-Provera®) 
− Contraceptive vaginal ring (e.g., NuvaRing®) 
− Transdermal contraceptive patches (e.g., Ortho Evra®) 
• Subjects of childbearing potential who are abstinent are eligible, but they must agree 
to use one of the birth control regimens listed above if they begin engaging in sexual 
activity that could lead to pregnancy during the study. 
Periodic abstinence e.g., calendar, ovulation, sympto-thermal, post-ovulation methods and 
withdrawal are not acceptable methods of contraception. 
Non-childbearing potential females are defined as females who are premenarchal, or 
postmenopausal (12 months with no menstrual period without an alternative medical cause), or 
who have undergone a hysterectomy, bilateral tubal ligation, bilateral oophorectomy (removal of 
the ovaries), or hysteroscopic sterilization. Documented verbal history from the subject is 
acceptable. 

Protocol FI-SC-001 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
 
Confidential 
 
Page 27 of 57 
10. 
STUDY ASSESSMENTS AND PROCEDURES 
10.1. 
Schedule of Study Visits and Assessments 
The study visit schedule visit windows and assessments and procedures and their associated 
timings are summarized in the Schedule of Events (Table 4). Every effort should be made to 
adhere to the study assessments and procedures, visit schedule and visit windows as specified in 
the Schedule of Events. Visit windows are calculated in relation to Baseline (Day 1). 
Additional information about the visits can be found in Section 10.2, and information about 
specific assessments and procedures can be found in Section 10.3. 
Study assessments and procedures will be performed only after signed informed consent is 
obtained. 
 

Protocol FI-SC-01 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
Confidential 
Page 28 of 57 
Table 4: 
Schedule of Events 
Visit → 
 
Assessment ↓ 
Screening 
Baseline 
(Day 1) 
Week 2 
(Day 15, -
1/+3 days) 
Week 4 
(Day 29, ±5 
days) 
Week 12/ 
End of 
Treatment 
(Day 85, 
±5days) 
Week 26 
(Month 6, 
±4 weeks) 
Week 52 
(Year 1, 
±4 weeks) 
Years 2-15* 
(52-week 
intervals, ±8 
weeks) 
Informed Consent 
X 
 
 
 
 
 
 
Eligibility Criteria 
X 
X 
 
 
 
 
 
Demographics 
X 
 
 
 
 
 
 
Medical/Surgical History 
X 
X 
 
 
 
 
 
Physical Exam/Vital Signs  
X 
X* 
X 
X 
X 
 
 
Skin Assessments 
X 
X 
X 
X 
X 
X 
 
Electrocardiogram 
X 
X 
X 
X 
X 
 
 
LoSCAT 
X 
X 
 
X 
X 
X 
 
Durometry 
 
X 
 
X 
X 
X 
 
SkinDex 
 
X 
 
 
X 
X 
 
(3) 3-4 mm biopsies/FCX-013 
X 
 
 
 
 
 
 
Inject FCX-013 
 
X 
 
 
 
 
 
Dispense/Collect Veledimex 
 
X 
X 
 
 
 
 
Prior/Concomitant Medications 
X 
X 
X 
X 
X 
X1 
X1 
Adverse Events 
X 
X 
X 
X 
X 
X2 
X2 
Hematology and Chemistry 
X 
X 
X 
X 
X 
 
 
HIV, Hep B, Hep C Testing 
X 
 
 
 
 
 
 
Urine Pregnancy Test, if applicable 
 
X 
X 
X 
X 
 
 
RCL Assay 
X 
 
 
 
X 
X 
X3 

Protocol FI-SC-01 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
Confidential 
Page 29 of 57 
Table 4: 
Schedule of Events (Continued) 
*include height and weight at Baseline 
 
An unscheduled visit, with necessary assessment, may occur as needed. 
Notes: 
a) 
For any subject who is diagnosed with or dies of a new malignancy, attempts will be made to collect a biopsy of the neoplastic tissue or pertinent autopsy tissue to perform 
relevant RCL testing. 
b) 
For any subject with a malignant growth in a region of FCX investigational gene therapy administration, attempts will be made to collect a skin biopsy of the malignant 
tissue for viral vector presence and potentially clonality of vector integration testing, as available. 
c) 
In years 1-5 only, a skin biopsy from the region of FCX investigational gene therapy administration (i.e., treated skin area) may be taken to test for relevant transgene and 
vector persistence in subjects who consent to the collection of the biopsies required to perform the assay. However, collection of biopsies will stop if transgene and vector 
persistence is undetected. 
*Long-term Follow-Up for years 2-15 may be performed by contacting the subject to review/record requested information, ideally scheduled to follow annual visits 
and assessment (including relevant laboratory analyses) performed by the subject’s health care provider. 
1. Report exposure to mutagenic agents and other medicinal products. 
2. Report adverse events of special interest and emergence of new clinical conditions, including, but not limited to: new malignancy, new incidence or exacerbation of a pre-
existing neurologic disorder, new incidence or exacerbation of a prior rheumatologic or other autoimmune disorder, new incidence of a hematologic disorder, unexpected 
illnesses and hospitalization(s). 
3. Collection and analysis of a blood sample to monitor for RCL may be performed yearly for up to 15 years. If all post-treatment RCL assays are negative through one year 
following subject’s final investigational product administration, collection of the yearly follow-up samples may be discontinued. 
 

Protocol FI-SC-01 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
Confidential 
 
Page 30 of 57 
10.2. 
Study Procedures by Visit 
Every effort should be made to adhere to the study assessments and procedures as outlined in the 
Schedule of Events (Table 4). 
Supplementary by-visit instructions are presented in this section. 
10.2.1. 
Prescreening and Screening (Visit 1) 
Prescreening 
An Investigator or designee may prescreen medical histories of potential subjects with localized 
scleroderma/morphea for potential inclusion into this study in accordance with their IRB’s policy 
on chart reviews. Some activities may include: 
• The Investigator may request additional PHI disclosure authorizations from the 
potential subject to assist with Pre-Screening. 
• Potentially eligible subjects may be mailed an IRB-approved information letter which 
includes a study overview, key inclusion/exclusion criteria, information about the 
recruitment process, and contact information. 
If a potential subject contacts the Investigative Site indicating interest in the study, an 
Investigator or designee reviews the letter contents with the subject and addresses questions. At 
this time the Investigator or designee can verbally review the inclusion / exclusion criteria. If the 
potential subject remains interested in participating in the study, a copy of the informed consent 
may be sent to the potential subject to review. 
Screening 
Screening evaluations may be conducted over multiple visits, however, informed consent must 
be obtained at the first screening visit and collection of biopsies for FCX-013 manufacturing 
should also be completed at the first screening visit, or as soon as possible thereafter. 
Written informed consent must be obtained from the subject prior to performing any study 
assessment or procedures. Provide subject with a copy of the signed and dated consent form, and 
document informed consent in the subject’s source documents and CRF. 
The Investigator will review all screening data when all test results are available. If screening test 
results received after manufacturing biopsies have been taken show the subject does not meet 
study criteria, the subject will be withdrawn (screen failure) and all material obtained for 
manufacturing will be destroyed unless consent has been obtained to use the tissue for future 
research. 
10.2.2. 
Baseline (Day 1) 
Subjects will be reassessed to confirm final eligibility to participate in the study.  
Physical and laboratory safety assessments, and the LoSCAT and durometry assessments should 
be performed, and the SkinDex 29+3 administered, prior to administration of FCX-013. 
Post-administration of FCX-013, AEs and concomitant medications should be assessed and 
recorded, as applicable. 

Protocol FI-SC-01 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
Confidential 
 
Page 31 of 57 
Veledimex should be provided, with instruction to initiate dosing with food that day and then 
daily for 14 days. 
10.2.3. 
Week 2 (Day 15) / Week 4 (Day 29) 
At Week 2, remaining veledimex should be collected, and the subject should be queried about 
their dosing compliance, including any dates of missed doses, and this information should be 
recorded. 
10.2.4. 
Week 12/End of Treatment 
If a subject discontinues from the study, every effort must be made to perform the End of 
Treatment study assessments and procedures. The primary reason for subject’s withdrawal from 
the study should be documented in the subject’s source documents and CRF. 
10.2.5. 
Long-Term Follow-Up 
During the long-term follow-up period, the subject, and/or their healthcare provider will be 
contacted annually to collect information regarding AEs, health changes and concomitant 
medications. 
Collection and analysis of a blood sample to monitor for RCL may be performed yearly for up to 
15 years. If all post-treatment RCL assays are negative through one year following subject’s final 
administration of FCX-013, collection of the yearly follow-up samples may be discontinued. 
For any subjects that require tissue biopsies (RCL, insertional mutagenesis, and/or transgene and 
vector persistence), please contact the sponsor for current procedures. 
10.2.6. 
Unscheduled Visit 
An unscheduled visit may occur during the study as necessary based on investigator’s 
judgement. At every unscheduled visit, AEs, health changes, and concomitant medications will 
be assessed. Additional procedures and assessments may be performed based on investigator’s 
judgment. 
10.3. 
Assessments 
10.3.1. 
Demographics 
Subject’s demographic information will be collected at the Screening visit and will include 
initials, date of birth (DOB), sex, and subject-reported race and ethnicity. 
10.3.2. 
Medical/Surgical History, Prior and Concomitant Medications 
Medical/surgical history will be collected at the Screening visit to ensure subjects are eligible for 
participation in the study (per inclusion Section 8.1 and exclusion Section 8.2 criteria). 
The Investigator or designee will collect a complete medical history at the Screening visit, 
including review of subject’s prior and concomitant medications (per Section 9.4). The medical 
history will include review and recording of dermatological (including scleroderma history), 
neurological, ophthalmic, ear/nose/throat, cardiovascular, respiratory, gastrointestinal, 

Protocol FI-SC-01 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
Confidential 
 
Page 32 of 57 
hematologic, endocrine, renal, hepatic, psychiatric and other conditions/diseases, as well as 
allergies (drug, food, environmental).  
The Investigator or staff must record all clinically or medically relevant information as medical 
history. 
10.3.3. 
Vital Signs 
Vital sign measurements include systolic and diastolic blood pressure, pulse, and respiratory rate 
as well as temperature. Blood pressure, pulse, and respiratory rate are taken after subjects are in a 
rested state. Blood pressure determined by cuff (manual or automated) is acceptable although the 
same method should be used throughout the study. Temperature, oral or tympanic, is acceptable 
although the same method should be used throughout the study. 
10.3.4. 
Physical Examination 
Body systems evaluated will include:  
• General appearance (include height and weight at Baseline) 
• HEENT (Head, Ears, Eyes, Nose, Throat)  
• Spine/Neck/Thyroid 
• Respiratory  
• Cardiovascular 
• Abdomen 
• Nervous System  
• Musculoskeletal 
Abnormalities or changes in severity noted during the exam should be reported in the source 
document and on the appropriate CRF page. If a new clinically relevant finding occurs (not noted 
prior to FCX-013 plus veledimex administration), an AE must be recorded. In addition, 
resolution of any abnormal findings during the study will be noted in the source document and 
appropriate CRF if clinically significant. 
Skin Assessments 
A qualified individual will perform a skin examination at all visits to the Investigative Site. If at 
any point in the study a skin cancer occurs in the region of the FCX-013 administration, attempts 
will be made to collect samples of the skin cancer to evaluate cells for the presence of viral 
vector. Biopsy and injection sites will be monitored for appropriate wound healing and adverse 
reactions. 
10.3.5. 
Electrocardiogram  
A 12-lead ECG and rhythm strip measurements will be made with the subject in a supine 
position having rested in this position for at least 10 minutes before each reading. ECG 
recordings will be digital, with paper tracings printed at a standard paper speed of 25 mm/sec and 
gain of 10 mm/mV, with a lead II rhythm strip. Intervals RR, PR, QRS, QT, QTcF, and QTcB 

Protocol FI-SC-01 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
Confidential 
 
Page 33 of 57 
will be calculated automatically and checked by a study physician. Individual ECG tracings will 
be stored digitally for independent assessment, if necessary. 
10.3.6. 
Skin Biopsy for FCX-013 Manufacturing 
Three (3) 3-4 mm skin biopsies for the purpose of FCX-013 manufacturing will be collected at 
the first Screening visit if at all possible. Biopsies will be collected from subject’s 
normal/unaffected/intact skin with the specific location varying on a case-by-case basis based on 
the Investigator’s judgment (refer to Appendix 1 for additional collection site guidance). 
An additional set of skin biopsies may be collected if the manufacturing process does not yield 
an FCX-013 cell count sufficient for at least one treatment session or does not meet release 
specifications. 
Biopsy collection procedures are provided in Appendix 1. Additional details regarding biopsy 
supply requisition, scheduling, collection, preparation and shipment of the biopsies to Fibrocell 
will be detailed in the Study Procedures Manual, as applicable. 
10.3.7. 
Laboratory Assessments: Hematology and Blood Chemistry 
Whenever possible, the amount of blood collected should be minimized.  
Serum chemistry and hematology laboratory analyses will occur locally. A copy of the reports 
will be maintained as part of the subject’s source documentation. 
Reference ranges will be supplied by the laboratory and used to assess the laboratory data for 
clinical significance and out-of-range pathological changes. Abnormal laboratory values which 
are unexpected or not explained by the subject’s clinical condition should be repeated until 
confirmed, explained or resolved. Changes from lab results after the Baseline (Day 1) will be 
recorded as an AE if deemed clinically relevant by the Investigator or medically qualified 
designee.  
The following laboratory evaluations will be conducted as indicated in the Schedule of Events 
(Table 4): 
Serum Chemistry / Metabolic Panel 
Albumin 
Alkaline Phosphatase  
Total Anion Gap 
ALT (SGPT) 
AST (SGOT) 
Urea Nitrogen  
Calcium  
Chloride 
Bilirubin, direct & 
indirect  
CO2 
Creatinine  
Glucose 
Globulin  
Potassium  
Sodium 
Total Protein 
Hematology / Complete Blood Count with Differential 
Hemoglobin  
Hematocrit 
Platelet Count 
RBC  
RDW 
MCV 
MCH 
MCHC 
WBC 
Neutrophils, % and absolute count  
Lymphocytes, % and absolute count 
Monocytes, % and absolute count  
Eosinophils, % and absolute count 
Basophils, % and absolute count 
HIV, Hepatitis B, and Hepatitis C Testing 

Protocol FI-SC-01 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
Confidential 
 
Page 34 of 57 
A blood sample for diagnostic screening tests for HIV antibodies, Hepatitis B surface antigen 
(HBsAg), and Hepatitis C (Hep C) antibody and PCR analysis will be collected at Screening, and 
the analyses will occur locally.  
Pregnancy Screen 
A urine pregnancy test will be performed as indicated in the Schedule of Events (Table 4) on all 
female subjects of childbearing potential (Section Section 9.5 ). Urine pregnancy testing must be 
performed locally, prior to FCX-013 administration. In the case of a positive pregnancy test, 
FCX-013 will not be administered. 
Pharmacokinetic Assessments 
No pharmacokinetic assessments will be performed in this study. 
10.3.8. 
Replication Competent Lentivirus Analysis 
A blood sample for RCL analysis will be collected at the time points indicated in the Schedule of 
Events (Table 4). A blood sample for RCL analysis is not required at Screening if previously 
performed within the past 2 years and results are contained in the subject’s medical records. If 
RCL analysis was performed >2 years from Screening, a discussion with the Medical Monitor 
should occur to determine if the testing timeframe is acceptable. Results must be available and 
reviewed prior to subject’s final eligibility determination on Day 1. If all post-treatment blood 
RCL assays for an individual subject are negative through one year following the subject’s final 
IP administration, collection of the yearly follow-up sample may be discontinued for that subject. 
If any post-treatment samples are positive, the result should be confirmed by conducting a 
biological-based (direct culture) assay and more extensive subject follow-up will be undertaken 
in consultation with the Sponsor and Center for Biologics Evaluation and Research (CBER). 
During the Long-Term Follow-Up portion of the study (as noted in the Schedule of Events), for 
any subjects that require RCL analysis of biopsies due to malignancies or other reasons, please 
contact the sponsor for current procedures. 
RCL analysis will occur at an outside lab. 
10.3.9. 
Durometry 
A durometer is a handheld device that can measure skin firmness or hardness. Durometric 
examination will be performed using a thin clear plastic (such as Saran wrap or thin report 
cover/page divider) to identify at least 3 anatomic markers and alignment around the target 
lesion(s).  The approximate center of the lesion should be identified and marked on this template, 
and the durometer should be centered over this area, with gentle pressure and complete contact, 
and a series of at least 3 readings should be obtained and recorded. If there are outlying readings, 
this should be repeated until 3 readings are reasonably concurrent, and these should be recorded. 
An average score will be calculated for each target lesion. The template used to identify the 
lesion and the center for readings should be retained for use at subsequent visits. The template 
may also be used to mark injection points.  
 

Protocol FI-SC-01 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
Confidential 
 
Page 35 of 57 
10.3.10. 
LoSCAT 
The Localized Scleroderma Assessment Tool (LoSCAT) (Appendix 3) should be completed by 
the Investigator to capture disease activity parameters. The LoSCAT is used to classify patients 
with morphea by disease severity and to identify clinically significant improvement in activity. 
Mild, moderate and severe activity corresponds with LoSCAT activity index (LoSAI ) scores of 
0–4, 5–12 and 13 and over, and with Physician's Global Assessment of activity (PGA ‐A) scores 
of 0–10, 11–30 and 31 and over. Mild, moderate and severe damage corresponds with LoSCAT 
damage index (LoSDI ) scores of 0–10, 11–15 and 16 and over, and with PGA of damage (PGA 
‐D) scores of 0–18, 19–30 and 31 and over.(Teske, 2020) 
Scores for each site will be based on the most severe score for each parameter. 
10.3.11. 
SkinDex 
The SkinDex 29+3 (Appendix 4)  is a skin-specific quality of life questionnaire which assesses 
three subscales: emotions, symptoms, and functioning in the month preceding administration. A 
fourth subscale was added to characterize morphea-specific concerns: (1) activity limitation as a 
result of disease, (2) concern for involvement of internal organs and (3) feelings of 
isolation.(Klimas, 2015) 
The SkinDex 29+3 will be administered by providing the questionnaire to the subject, who will 
be instructed to respond to each question. Study staff will review the questionnaire upon 
completion and will return it to the subject and ask that they respond to any incomplete lines. 
The responses will be summed at each applicable timepoint. 

Protocol FI-SC-01 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
Confidential 
 
Page 36 of 57 
11. 
STUDY DRUG MATERIALS AND MANAGEMENT 
11.1. 
Study Drug Materials and Administration 
11.1.1. 
FCX-013 
FCX-013 will be manufactured from one set of three 3-4 mm biopsies obtained at the Screening 
Visit. Upon receipt of the biopsies at Fibrocell, FCX-013 will be manufactured by gene 
modification and expansion of dermal fibroblasts obtained from the biopsy. The tissue will be 
digested with enzymes to release the fibroblasts, which will then be seeded into a tissue culture 
vessel. The cells will be expanded, transduced with INXN-2005 (a lentiviral vector encoding the 
functional MMP-1 gene), and expanded further. If the manufacturing process does not yield an 
FCX-013 cell count sufficient for at least one administration, or does not meet manufacturing 
release specifications, an additional set of biopsies may be requested from the subject. 
This IP will be provided to the Investigative Site as an opaque cell suspension in 2.0 mL 
cryovials containing approximately 1.2 mL of FCX-013 with a recoverable volume of 1.0 mL 
per vial. 
Packaging and Labeling 
Up to five (5) vials of FCX-013 will be provided per subject, per treatment session. The vials 
will be labeled with a minimum of the subject number and the date of manufacture. The 
secondary container in which the vials are shipped will include the following information: 
• IP Name: FCX-013 
• Lot Number 
• Fill Date and Time 
• Expiration Date and Time 
• Nominal Conc./Vol.: 10-30 million cells/mL in 1.0 mL  
• Manufactured by Fibrocell Technologies Inc. Exton, PA 
• CAUTION: NEW DRUG – Limited by US Federal Law to Investigational Use  
• NOT EVALUATED FOR INFECTIOUS SUBSTANCES 
The cells will be transported to the investigative site as a suspension and the vial will be 
packaged in a temperature controlled and monitored shipper and delivered by overnight courier. 
Storage 
After receipt of the shipped vials, they must be kept sealed in the shipper until ready for use. The 
Investigator will be responsible for accurate, written records of all FCX-013 received. The 
Sponsor or designee will be permitted upon request to audit the administration procedures and 
records. 
FCX-013 Drug Product will be shipped same day or overnight delivery to the clinic and must be 
administered within 40 hours of the fill time as indicated on the label.  

Protocol FI-SC-01 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
Confidential 
 
Page 37 of 57 
Preparation and Administration 
One administration of FCX-013 is up to 4 mL of cell suspension administered in up to sixteen 
(16) 0.25 mL intradermal injections. 
The maximum dose of FCX-013 will be determined by characteristics of the lesion(s) chosen. 
Approximately 100 million cells will be administered at each dose administration. One 
administration of FCX-013 will consist of a maximum of 4 mL of FCX-013 administered in up 
to sixteen (16) 0.25 mL intradermal injections. The injections will be administered in and across 
the sclerotic area of target lesion(s). The Investigator will attempt to administer all 4mL of FCX-
013. This will be accomplished by selecting target lesions that are as close as possible to 16 
linear cm. 
Table 5 provides details regarding the number of cells, vials and injections per administration. 
Table 5: 
FCX-013 Cell Count and Injections per Administration 
 
FCX-013 Cells 
~100 million 
Concentration of FCX-013 Suspension 
10-30 million cells/mL 
# Vials 
Up to 5 
Injections per Vial 
1 
Cells per Injection 
6 million 
Number of Injections 
Up to 16 
 
11.1.2. 
Veledimex 
The veledimex product is supplied as a 50 mg/g Solutol™ formulation, encapsulated in Licaps® 
hard gelatin capsules to produce veledimex at a strength of 40 mg per capsule. 
Packaging and Labeling  
The manufacturing location may be revised during the course of the study. 

Protocol FI-SC-01 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
Confidential 
 
Page 38 of 57 
Storage 
The primary container closure system for veledimex drug product packaged clinical supplies is 
75 cc white HDPE, round bottle with 33 mm white child resistant closure. 
Veledimex capsules should be stored at room temperature under dry conditions. Intact veledimex 
capsules can be considered to be nontoxic and can be safely handled without special precautions. 
Preparation and Administration 
For the current study, veledimex is intended to be administered once daily at a maximum daily 
dose of 160 mg (4 capsules containing 40 mg veledimex each). 
11.2. 
Study Drug Accountability 
An accurate record of all supplies received and used at each site should be maintained and 
updated regularly. 
Subject will be instructed to return all veledimex capsules at specified protocol visits for study 
treatment inventory and assessment of subject compliance. 
The dispensing and return of all veledimex will be recorded on the study Investigational Product 
Dispensing Record. The Subject Number and the initials and date of the person dispensing and 
receiving the returned treatment will be documented on this form. 
Inventory records must be readily available for inspection by the study monitor and/or auditor, 
and open to inspection by regulatory authorities at any time. 
11.3. 
Study Drug Handling and Disposal 
After receipt of the shipped vials, they must be kept sealed in the shipper until ready for use. The 
Investigator will be responsible for accurate, written records of all FCX-013 received. The 
Sponsor or designee will be permitted upon request to audit the administration procedures and 
records. 
FCX-013 Drug Product will be shipped same day or overnight delivery to the clinic and must be 
administered within 40 hours of the fill time as indicated on the label. 

Protocol FI-SC-01 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
Confidential 
 
Page 39 of 57 
12. 
ADVERSE EVENTS 
Adverse events will be collected from the time the subject signs the informed consent form (ICF) 
until the final visit/contact with the subject.  
At each visit/contact, the Investigator or designee is responsible for reviewing, documenting, and 
reporting events that meet the definition of an AE. 
Subjects should be asked a non-leading question in order to avoid bias in eliciting AEs, such as 
“Have you had any changes in your health since your last visit?” at each visit/contact. It is 
important to question the subject in a non-leading way about changes in their health or 
concomitant medication usage since their last visit. 
* For any subject who develops an AE suggestive of a retrovirus-associated disease after FCX-
013 treatment, attempts will be made to collect any relevant clinical samples for available RCL 
testing 
*For any subject who dies or is diagnosed with a neoplasm after FCX-013 treatment, attempts 
will be made to collect a biopsy of the neoplastic tissue or pertinent autopsy tissue to assay for 
available RCL testing by qPCR. 
Following the subject’s initial report of an AE, the Investigator or designee is required to 
proactively follow-up with the subject regarding any previous AE that hasn’t resolved at 
subsequent visits/contacts. 
12.1. 
Adverse Event Definitions 
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether 
or not considered drug related. An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, disease or exacerbation of a pre-existing 
condition temporally associated with the use of a medicinal (investigational) product. 
Signs and/or symptoms of the disease under study/lack of efficacy should not be considered as 
AEs, as long as they are within the normal day-to-day fluctuation or expected progression of the 
disease. However, significant worsening (e.g., increase in severity or frequency) of the signs 
and/or symptoms should be recorded as an AE. Any clinically significant change from 
Screening, based upon the opinion of the Investigator, in physical or examination findings and/or 
vital signs should be recorded as an AE. 
A change in the value of a safety laboratory evaluation can represent an AE if the change is 
clinically significant, based upon the opinion of the Investigator, or if, during treatment with the 
IP, a shift of a parameter is observed from a normal value to a pathological value, or a further 
worsening of an already pathological value. When evaluating such changes, the extent of 
deviation from the reference range, the duration until return to the reference range, either while 
continuing treatment or after the end of treatment with the IP, and the range of variation of the 
respective parameter within its reference range, should be taken into consideration. The 
Investigator should decide, based on the above criteria and the clinical condition of the subject, 
whether a change in a laboratory parameter represents an AE. For pathological laboratory values 
that were not present prior to IP administration, follow-up laboratory evaluations should be 
performed until the values return to within reference range or until a plausible explanation is 
found. 

Protocol FI-SC-01 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
Confidential 
 
Page 40 of 57 
Any AE occurring after administration of IP will be considered a TEAE. 
Examples of events meeting the definition of an AE include: 
• Any abnormal laboratory test results (hematology, chemistry) or other safety 
assessments (e.g., physical examination, vital signs measurements), including those 
that worsen from Screening, and felt to be clinically significant based upon the 
medical and scientific judgment of the Investigator; 
• Exacerbation of a chronic or intermittent pre-existing condition (e.g., asthma) 
including either an increase in frequency and/or intensity/severity of the condition; 
• New conditions detected or diagnosed after Screening. 
Examples of events that do not meet the definition of an AE include: 
• Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments that are associated with the underlying disease, unless judged by the 
Investigator to be more severe than expected for the subject’s condition (e.g., 
anemia); 
• The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the subject’s 
condition or if these events meet the criteria as SAEs or leads to discontinuation of 
FCX-013 or from the study; 
• Medical or surgical procedure (e.g., endoscopy, appendectomy); the condition that 
leads to the procedure is an AE; 
• Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen. 
12.1.1. 
Serious Adverse Event 
An AE or suspected adverse reaction is considered "serious" if, in the view of either the 
investigator or sponsor, it results in any of the following outcomes: 
• Death 
• A life-threatening AE 
− An AE or suspected adverse reaction is considered "life-threatening" if, in the 
view of either the investigator or sponsor, its occurrence places the subject at 
immediate risk of death. It does not include an AE or suspected adverse reaction 
that, had it occurred in a more severe form, might have caused death) 
• Inpatient hospitalization or prolongation of existing hospitalization 
− Emergency room visits that do not result in admission to the hospital should be 
evaluated for one of the other serious outcomes (e.g., life-threatening; required 
intervention to prevent permanent impairment or damage; other serious medically 
important event). 

Protocol FI-SC-01 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
Confidential 
 
Page 41 of 57 
• A persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions 
• A congenital anomaly/birth defect 
• Important medical events that may not result in death, be life-threatening, or require 
hospitalization may be considered serious when, based upon appropriate medical 
judgment, they may jeopardize the subject and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition. Examples of such 
medical events include allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in 
inpatient hospitalization, or the development of drug dependency or drug abuse. 
• Any event that does not exactly meet this definition yet, in the investigator’s opinion 
represents a significant hazard can be assigned the “important medical events” 
regulatory reporting serious criteria. 
12.2. 
Reporting Procedure 
All AEs observed by the Investigator or site staff or reported by the subject or their caregiver 
(whether or not attributed to IP), must be fully and completely documented in the subject’s 
source documents and CRF. In the event a subject is withdrawn from the study because of an 
AE, the primary reason for withdrawal (i.e., due to an AE) must be recorded on the CRF as such. 
Each AE requires a complete description including event description (where possible, a 
diagnosis or if a diagnosis has not been made, individually listed sign(s)/symptom(s)), date of 
onset and resolution, if applicable, outcome (refer to Section 12.2.2), and actions taken to be 
recorded in the source documents. The Investigator must also assign the following attributes for 
each AE: its relationship to the IP (refer to Section 12.2.3) and severity of the AE (refer to 
Section 12.2.4). The Investigator may be asked to provide follow-up information. 
12.2.1. 
SAE Reporting Procedure 
The Investigator or designee must report any SAE to the Sponsor or its designee immediately 
(within 24 hours (1 working day)) following becoming aware of the event even if the SAE does 
not appear to be related to IP. This timeframe also applies to becoming aware of additional new 
information (follow-up) on previously reported SAEs. 
Do not delay reporting a suspected SAE in order to obtain additional information. Any additional 
information, if collected, can be reported as a follow-up to the initial report. Prompt notification 
of SAEs by the Investigator to the Sponsor is essential so that legal obligations and ethical 
responsibilities towards the safety of subjects and the safety of a product under clinical 
investigation are met. 
If the subject was permanently withdrawn from the study due to the SAE, this information must 
be reported in either the initial or follow-up SAE report, and in the End of Study CRF. 
For any deaths reported, available autopsy reports and relevant medical reports should be 
provided with the SAE report. 

Protocol FI-SC-01 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
Confidential 
 
Page 42 of 57 
Specific details regarding the applicable forms, process and contacts for SAE reporting will be 
provided in the Study Procedures Manual. 
The Investigator or designee should notify the IRB of SAEs occurring at the site and other SAE 
reports received from the Sponsor or its designee, in accordance with IRB procedures. The 
Sponsor will be responsible for notifying the relevant authorities of any SAE according to 
applicable regulations. 
12.2.2. 
Follow-Up of Adverse Events 
Following the subject’s initial report of an AE, the Investigator or designee is required to 
proactively follow-up with the subject regarding any previous AE that hasn’t resolved at 
subsequent visits/contacts. 
Where possible, all AEs should be followed to resolution. Medically significant AEs considered 
related to the IP by the Investigator or the Sponsor will be followed until resolved or considered 
stable. Medical tests and examinations will be performed, as appropriate, to document resolution. 
All SAEs will be followed until the Sponsor agrees that the event is satisfactorily resolved or that 
no further follow-up is required. 
The Investigator will assess the outcome of each AE using the following criteria: 
• Recovered/Resolved:  The event has improved or subject recuperated. 
• Recovered/Resolved with sequelae:  The subject has recuperated but retained 
pathological conditions resulting from the prior disease or injury. 
• Recovering/Resolving:  The event is improving. 
• Not recovered/Not resolved:  The event has not improved, or subject has not 
recuperated. 
• Unknown:  The outcome of the event is not known, not observed, not recorded, or 
refused. 
• Fatal:  Termination of life as an outcome of the AE. 
12.2.3. 
Relationship of Adverse Event to Investigational Product 
The relationship of an AE to IP is to be assessed by the PI using good clinical judgement and 
according to the following definitions: 
• Not Related – no temporal association or the cause of the event has been identified, or 
the drug cannot be implicated based upon available information. 
• Possibly Related – temporal association, but other etiologies are likely to be the 
cause.  However, involvement of the drug cannot be excluded, based upon available 
information. 
• Definitely Related – established temporal or other association (e.g., re-challenge) and 
event is not reasonably explained by the subject’s known clinical state or any other 
factor, based on available information. 

Protocol FI-SC-01 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
Confidential 
 
Page 43 of 57 
12.2.4. 
Severity of Adverse Event 
The Investigator will make an assessment of the severity of each AE and SAE according to the 
National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), 
v. 5.0, 2017. 
For terms not specified in the CTCAE, the criteria in Table 6 should be used to determine the 
grade severity. 
Table 6: 
Criteria for Determining the Grade/Severity of Adverse Event Terms Not 
Specified by the NCI CTCAE Criteria 
Grade 
Criteria 
1 
Mild; asymptomatic or mild symptoms, clinical or diagnostic observations only; intervention not 
indicated 
2 
Moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate 
instrumental activities of daily livinga 
3 
Severe or medically significant but not immediately life-threatening; hospitalization or prolongation 
of hospitalization indicated; disabling; limiting self-care activities of daily livingb 
4 
Life threatening consequences; urgent intervention indicated 
5 
Death related to adverse event 
CTCAE = Common Terminology Criteria for Adverse Events. 
a  Instrumental activities of daily living refer to preparing meals, shopping for groceries or clothes, using the telephone, 
managing money, etc. 
b Self-care activities of daily living refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, 
and not bedridden. 
12.3. 
Pregnancy 
Should a pregnancy occur, it must be reported and recorded on Fibrocell’s pregnancy form. 
Pregnancy in itself is not regarded as an AE unless there is a suspicion that an IP may have 
interfered with the effectiveness of a contraceptive medication. 
The outcome of all pregnancies (spontaneous miscarriage, elective termination, normal birth or 
congenital abnormality) must be followed up and documented even if the subject was 
discontinued from the study. 
All reports of congenital abnormalities/birth defects are SAEs. Spontaneous miscarriages should 
also be reported and handled as SAEs. Elective abortions without complications should not be 
handled as AEs. 

Protocol FI-SC-01 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
Confidential 
 
Page 44 of 57 
13. 
STATISTICS 
Pre-designed CRFs will be used to collect data for analyses. A clinical database will be managed 
by a sponsor’s representative for this study. The database will be constructed based on the CRF 
data entry plus laboratory data information. Data queries will be generated and resolved. In 
addition, range checks of the CRF fields, plausibility and consistency checks across CRF pages 
will be performed to assess consistency, accuracy and completeness of the data collected and 
entered into the CRF. Standard SAS datasets will be generated and provided for analysis. 
13.1. 
Sample Size Determination 
Since this is primarily a safety study, no formal sample size determination is or was made. 
13.2. 
Analysis Populations 
Full Analysis Set 
The primary population for analysis of efficacy is the full analysis set (FAS). The FAS 
population includes subjects who were administered FCX-013. 
Per-Protocol 
The per-protocol (PP) population is defined as all subjects in the FAS who complete the Week 
12 assessments within the specified visit windows, and who do not meet any of the following 
criteria: 
• Did not receive intradermal injections of FCX-013 in the treated lesion(s); 
• Did not receive at least 10 doses of veledimex within 15 days of administration of 
FCX-013; 
• Other significant protocol violations, including medically significant violations of 
inclusion/exclusion criteria or prohibited medications/treatments which may 
reasonably affect clinical assessments. 
Safety 
The safety population includes subjects who were administered FCX-013. 
13.3. 
Demographic and Baseline Characteristics 
The descriptive summaries of subjects’ demographic and baseline characteristics will be 
presented. A detailed description of subject disposition will be provided. 
Subject characteristics will include a summary of the following: 
Subject demographics. 
Baseline disease characteristics as determined at screening. Pre-existing medical conditions. 
Continuous variables will be summarized using number of observations, mean and standard 
deviation, median and minimum and maximum values. Categorical values will be summarized 
using number of observations and percentages. 

Protocol FI-SC-01 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
Confidential 
 
Page 45 of 57 
13.4. 
Safety Analyses 
Subject demographics and relevant baseline data will be listed and described. Inclusion and 
exclusion criteria ensure that participants are suitable for the study. Premature termination will 
be described. 
Physical examinations, vital signs, ECG data, concomitant medications, and laboratory results, 
including RCL analyses will be listed, and relevant changes will be described by subject and 
overall, as applicable. 
Adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) 
AE dictionary. Adverse events will be grouped into pre-treatment AEs and TEAEs and will be 
described by preferred terminology and by body system. The number of adverse event entries, as 
well as the number of subjects will be described, including by AE type, relationship to FCX-013 
plus veledimex, seriousness, and severity of AEs. 
13.5. 
Efficacy Analyses 
All subjects who were administered FCX-013 and had at least one assessment of the target lesion 
post-administration will be included in the efficacy population. 
The change from baseline in the LoSCAT and durometry scores (average score at each 
applicable timepoint) will be reported descriptively, as will changes in the SkinDex 29+3 scores. 
The primary method of handling data will be last observation carried forward (LOCF). 
13.6. 
Interim Analysis 
There will be no formal interim analysis. 
13.7. 
Handling of Missing and Incomplete Data 
For efficacy evaluation, the treatment endpoint will be defined as one assessment time point, 
which includes the last measurement obtained during the study for a variable. No other 
imputation of values for missing data will be performed. Standard clinical monitoring and data 
management practices will be used to ensure the integrity of data. 

Protocol FI-SC-01 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
Confidential 
 
Page 46 of 57 
14. 
ETHICS AND GENERAL STUDY CONDUCT 
CONSIDERATIONS 
14.1. 
Ethical Conduct of the Study 
The Investigator will ensure that this study is conducted in accordance with the principles of the 
“Declaration of Helsinki” (as amended in Edinburgh, Tokyo, Venice, Hong Kong, and South 
Africa), ICH guidelines, or with the laws and regulations of the country in which the research is 
conducted, whichever affords the greater protection to the study subject. As this study is 
conducted under a US Investigational New Drug application (IND), the Investigator will ensure 
that the basic principles of “Good Clinical Practice,” as outlined in 21 Code of Federal 
Regulations (CFR) 312, subpart D, “Responsibilities of Sponsors and Investigators,” 21 CFR, 
part 50 and 21 CFR, part 56 are adhered to.  
Since this is a “covered” clinical trial, the Investigator will ensure that 21 CFR, part 54 is 
adhered to. This requires that the PI and all Sub-Is must provide documentation of their financial 
interest or arrangements with the Sponsor, or proprietary interests in the IP being studied. This 
documentation must be provided before participation of the PI and any Sub-I. The PI and Sub-Is 
agree to promptly notify the Sponsor or its designee if any relevant changes occur during the 
course of the study and for 1 year following completion of the study. Study completion is 
defined as the date that the last subject has completed the protocol-defined activities. 
14.2. 
Institutional Review Board 
This study will be conducted in full compliance with the United States (US) CFR for IRBs 21 
CFR, part 56. Before enrollment of subjects into the study, this protocol and any material to be 
provided to or seen by the subject (e.g., subject information letters, informed consent/assent 
forms, descriptions of the study used to obtain informed consent/assent, advertising material) 
will be submitted to an appropriate IRB for review and approval. Approval from the IRB must be 
obtained before starting the study and should be documented in a letter to the Investigator 
specifying the protocol number, protocol version, protocol date, documents reviewed, and date 
on which the committee met and granted the approval. IRB approvals must be sent to the 
Sponsor or its designee before initiation of the study. 
Any amendments or modifications made to the protocol or any accompanying material to be 
provided to the subject after receipt of IRB approval must also be submitted to the IRB for 
review and approval before implementation. 
The Investigator, or designee, will be responsible for obtaining IRB approval/renewal throughout 
the duration of the study at the frequency specified by the IRB. Copies of the investigator’s 
reports and the IRB written continuance of approval must be sent to the Sponsor or its designee.  
The Investigator, or designee, should notify the IRB of important deviations from the protocol 
and any SAEs occurring at the site or other SAE reports received from the Sponsor or its 
designee, in accordance with IRB procedures.  
All correspondence with the IRB must be retained in the study regulatory files. 

Protocol FI-SC-01 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
Confidential 
 
Page 47 of 57 
14.3. 
Subject Information and Consent 
14.3.1. 
General Provisions 
Informed consent is a process that is initiated prior to the subject’s agreement to participate in the 
study and continues throughout the subject’s study participation.  
Informed consent will be obtained in accordance with the Declaration of Helsinki, ICH GCP, US 
CFR for Protection of Human Subjects 21 CFR, part 50, subpart B (§50.20, §50.25, §50.27), 
subpart D as applicable, the Health Insurance Portability and Accountability Act (HIPAA), if 
applicable), and local regulations.  
The Investigator or designee will prepare an ICF and HIPAA authorization, as applicable and 
provide the documents to the Sponsor or its designee for approval prior to submission to the IRB. 
The ICF must contain the basic required elements of consent and additional elements, as 
applicable, as specified in 21 CFR subpart B §50.25 and will also comply with local regulations. 
Agreement from the Sponsor or its designee must also be obtained for all changes to the ICF. 
The Investigator or designee is responsible for obtaining written informed consent/assent from 
the subject or legally authorized representative (see note below) before any protocol-specific 
procedures are performed. Informed consent/ will be obtained after a full explanation of the 
purpose of the study, risks and discomforts involved, potential benefits, etc. have been provided 
in both oral and written form. The subject be given ample opportunity to inquire about details of 
the study. The ICF that is used must be the current IRB approved version and must be signed and 
personally dated by the subject and by the person who obtained the consent (not necessarily an 
investigator). 
NOTE: A legally authorized representative is an individual or judicial or other body 
authorized under applicable law to consent on behalf of a prospective subject to the subject’s 
participation in the procedure(s) involved in the research.  
If a potential subject is illiterate or visually impaired and does not have a legally authorized 
representative, the Investigator or designee must provide an impartial witness to read the 
informed consent form to the subject. Thereafter, both the subject and the impartial witness must 
sign the informed consent form to attest that informed consent was freely given and understood. 
The acquisition of informed consent should be documented in the subject’s medical records. A 
copy of the signed consent form must be provided to the subject and the original will be 
maintained with the subject’s records.  
It is the responsibility of the PI to ensure that any individual delegated the responsibility for 
obtaining consent are familiar with and adhere to the applicable consent/assent requirements. 
14.4. 
Protocol Compliance 
The Investigator is responsible for ensuring the study is conducted in accordance with the 
procedures and evaluations described in this protocol. 

Protocol FI-SC-01 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
Confidential 
 
Page 48 of 57 
14.5. 
Changes to the Protocol 
Protocol modifications or amendments, except those intended to reduce immediate risk to study 
subjects, may be made only by the Sponsor. IRB approval must be obtained before changes can 
be implemented. The Investigator or designee must send a copy of the IRB protocol amendment 
approval letter to the Sponsor or its designee.  
Emergency departures from the protocol that eliminate an apparent immediate safety hazard to a 
particular subject and that are deemed by the Investigator as crucial for the safety and wellbeing 
of that subject may be instituted for that subject only and documented as a deviation. The 
Investigator will contact the Medical Monitor as soon as possible regarding such a deviation. 
These departures do not require preapproval by the IRB; however, the IRB and Medical Monitor 
must be notified in writing as soon as possible in accordance with the IRB policies after the 
departure has been made. 
14.6. 
Posting of Information on Publicly Available Clinical Trial Registers 
Study information from this protocol will be posted on publicly available clinical trial registers 
before enrollment of subjects begins as required. Results will be posted as required. 
14.7. 
Study Documentation 
The Investigator must maintain adequate and accurate records to enable the conduct of the study 
to be fully documented and the study data to be subsequently verified.  
14.7.1. 
Investigator Study File  
The Investigator and study staff are responsible for maintaining a comprehensive and centralized 
filing system of all study-related (essential) documentation, in a complete, accurate, and legible 
manner, suitable for inspection at any time by representatives from the Sponsor, companies that 
work for and with the Sponsor, applicable regulatory agency(ies), and/or the IRB. 
Investigator Study File elements should include, but are not limited to, the following: 
• Subject files containing completed CRFs, informed consents/assents, and source 
documentation. 
• Study files containing the protocol with all amendments, investigator’s brochure, 
copies of pre-study documentation along with any updates, all correspondence to and 
from the IRB (submissions and approvals), Study Procedures Manual, CRF 
Completion Guidelines, study logs (e.g., subject identification, screening, delegation, 
site visit), deviations, biological sample records, SAE and IND safety reports / Safety 
Alert Letters and relevant correspondence with the Sponsor and/or its designee. 
• IP accountability (e.g., receipt, dispensing, administration, return/destruction) records 
and all IP-related correspondence. 
14.7.1.1. Subject’s Source Documentation 
The Investigator must maintain detailed and accurate records (other than the CRF) on all study 
subjects. The subject’s source documents are original documents, data, and records from which 
the subject’s CRF data are obtained. These include but are not limited to the original 

Protocol FI-SC-01 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
Confidential 
 
Page 49 of 57 
signed/dated informed consent/assent, HIPAA authorization, hospital records, clinical and office 
charts, laboratory/diagnostic testing results, pharmacy/drug accountability records, diaries, 
microfiches, radiographs, photographs and correspondence. Telephone conversations with the 
subject, subject’s legal authorized representative and/or the Sponsor or its designee concerning 
the subject must also be recorded and retained. 
14.7.1.2. Pre-Study Documentation Requirements 
The Investigator or designee is responsible for providing the following documentation to the 
Sponsor or its designee for review prior to study enrollment. Any updates of the documentation 
must also be provided, as applicable, during the conduct of the study. 
• Signed and dated investigator’s brochure (IB) receipt form 
• Signed and dated protocol signature page (Investigator’s Agreement) 
• A blank copy of the IRB-approved informed consent form (and assent documents, if 
applicable) 
• Copy of the IRB approval of the protocol, information letter, consent form, and assent 
form, as applicable 
• Completed Food and Drug Administration (FDA) Form 1572. Local laboratories, 
laboratories providing endpoint data and any central laboratories for the study must 
be listed on the form.  
• Up-to-date curriculum vitae or equivalent for each person listed on the Form FDA 
1572  
• Signed Financial Disclosure Form for each person listed on the Form FDA 1572  
• IRB membership list 
• The IRB composition and/or written statement that IRB is in compliance with 
regulations  
• Local laboratory(ies) normal ranges 
• Documentation of the local laboratory(ies) certification/licenses (e.g., CAP/CLIA or 
other) or equivalent 
• A fully executed Clinical Trial Agreement  
14.8. 
Data Collection, Management, Monitoring, and Retention 
14.8.1. 
Data Collection and Management 
For this study, subject data will be entered into the Sponsor-defined CRFs and combined with 
data provided from other sources, as applicable, in a validated data system. Data will be 
appropriately documented in the subject’s source documents and entered into the CRF when the 
information is available. Applicable data from the subject’s source documents should be 
recorded in the CRFs completely and promptly. Completed CRFs should be ready for review by 
the Sponsor or its designee within one (1) week of each study visit for any given subject. 

Protocol FI-SC-01 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
Confidential 
 
Page 50 of 57 
Management of clinical data will be performed in accordance with applicable Sponsor’s or its 
designee’s standards and data cleaning procedures will be used to ensure the integrity of the data, 
e.g., errors will be corrected, and inconsistencies queried in the data. 
Adverse events and relevant medical history will be coded using MedDRA. Concomitant 
medications will be coded using the World Health Organization Drug Global Dictionary 
(WHODrug Global). 
Corrections of data entered into the CRF must be made on the CRF or in the system for 
electronic CRF and supported by source documents, as appropriate. Corrections to the eCRF 
through queries and comments will be tracked by the eCRF internal audit trail. 
The Investigator is responsible for all information collected on study subjects enrolled in this 
study. The data collected during the course of this study must be reviewed and verified for 
completeness and accuracy by the Investigator. After a full review of the CRFs by the Sponsor or 
its designee and resolution of any data clarifications, the Investigator will review, sign, and 
approve the subject’s CRF. 
If an electronic CRF is utilized, copies of the final completed CRFs will be provided on a data 
storage device (e.g., USB flash drive) for archiving at the investigative site following database 
lock and at or prior to study closure. 
14.8.1.1. Subject Confidentiality 
The investigator must take all reasonable measures to ensure that the subject’s confidentiality is 
maintained. Study subjects will not be identified by name in the study database or on any study 
documents to be collected by the Sponsor or its designee. On the CRFs or other documents 
submitted to the Sponsor and those working with the Sponsor, subjects should be identified by 
their initials, date of birth as applicable, site number, study subject number, and/or unique 
clinical identification number as applicable only. The Investigator must keep a log showing study 
subject numbers, names, and addresses for all subjects enrolled in the trial. Documents that are 
not for submission to the Sponsor or those working with the Sponsor should be kept in strict 
confidence by the Investigator.  
In compliance with Federal regulations/ICH GCP Guidelines, the Investigator and Institution 
shall permit authorized representatives of the Sponsor and companies that work with the 
Sponsor, regulatory agency(ies), and the IRB direct access to review the subject’s original 
medical records for verification of study-related procedures and data. Direct access includes 
examining, analyzing, verifying, and reproducing any records and reports that are important to 
the evaluation of the study. The Investigator is obligated to inform and obtain the consent of the 
subject to permit such named representatives to have access to his/her study-related records 
without violating the confidentiality of the subject. 
14.8.1.2. Data Quality Control and Reporting 
After data have been entered into the study database, a system of computerized data validation 
checks will be implemented and applied to the database on a regular basis. Queries may be 
entered, tracked, and resolved through the electronic data capture (EDC) system directly. The 
study database will be updated in accordance with the resolved queries. All changes to the study 
database will be documented. 

Protocol FI-SC-01 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
Confidential 
 
Page 51 of 57 
14.8.1.3. Monitoring/Auditing 
Representatives of the Sponsor, following ICH Guidelines for GCP (E6), will monitor the 
conduct of this study at regular intervals to verify adherence to the protocol; completeness, 
accuracy, and consistency of the data entered into the CRFs; and adherence to Federal and local 
regulations on the conduct of clinical research. In addition, audits or inspections may be carried 
out by the Sponsor’s or its designee’s independent Quality Assurance Department, the FDA, 
local regulatory authority or the IRB. In accordance with ICH Guidelines for GCP, the 
Investigator must provide direct access to all study records including subject’s source 
data/documents (e.g., subject’s medical records), CRFs, and other study related documents (e.g., 
Investigator Study File, IP drug accountability records). In addition, the Investigator agrees to 
provide to representatives of the Sponsor, regulatory agency or IRB access to facilities and 
personnel necessary for the effective conduct of any inspection or audit. 
To ensure compliance with GCPs and all applicable regulatory requirements, authorized 
representatives of the Sponsor may conduct a quality assurance audit. The purpose of a Sponsor 
audit is to systematically and independently examine all study-related activities and documents 
to determine whether these activities were conducted, and data were recorded, analyzed, and 
accurately reported according to the protocol and any supporting documentation, ICH Guidelines 
for GCP, and any applicable regulatory requirements.  
The Investigator agrees to cooperate with the Sponsor’s representatives to ensure that any 
problems detected in the course of monitoring and/or audit visits, including delays in completing 
CRFs, are resolved in a timely manner. 
In addition, authorized representatives of regulatory agency(ies) and/or an IRB may visit the site 
to perform audits or inspections. If the Investigator is notified of an inspection by a regulatory 
authority the Investigator agrees to notify the Sponsor immediately. 
14.8.1.4. Retention of Records 
All study documents (e.g., subject files, signed informed consent forms, copies of CRFs, 
Investigator Study File notebook, etc.) must be kept secure and retained by the Investigator until 
at least 2 years after the last approval of a marketing application in an ICH region (i.e., USA, 
Europe, or Japan) and until there are no pending or contemplated marketing applications in an 
ICH region; or, if no application is filed or if the application is not approved for such indication, 
until 2 years after the investigation is discontinued and regulatory authorities have been notified. 
Investigators may be required to retain documents longer if required by applicable regulatory 
requirements, by local regulations, or by an agreement with the Sponsor. 
The Investigator must notify and receive prior written consent of the Sponsor before any study 
documents are destroyed, moved to another location, or assigned to another party. 
14.9. 
Future Use of Stored Specimens and Data 
Biopsy specimens and manufactured drug substance may be stored for future manufacturing of 
Drug Product (FCX-013) for use by the subject in future clinical trials or following FCX-013 
commercialization, if applicable. 
With the subject’s approval, biopsy specimens and fibroblasts obtained for the manufacture of 
FCX-013 may be stored in a cell bank and be available for research, including manufacturing 

Protocol FI-SC-01 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
Confidential 
 
Page 52 of 57 
process development research, genetic analysis, preclinical or clinical comparison experiments 
for any cell-based gene-therapy where production of MMP1 may be beneficial. Samples retained 
for additional future research will be de-identified. Only employees of Fibrocell and/or agents 
contracted by Fibrocell for the purpose of conducting the research, will have access to the 
samples and data. However, Fibrocell may contract with secondary experts or laboratories to 
conduct additional research.   
14.10. 
Publication Policy 
The information provided in support of or generated as a result of this study is confidential. Any 
use or reproduction thereof, including but not limited to publications or presentations by the 
Investigator or his/her associates, must be submitted to the Sponsor for review and approval prior 
to publication or presentation in any form. All publications must acknowledge the sponsorship.  
 
 

Protocol FI-SC-01 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
Confidential 
 
Page 53 of 57 
15. 
REFERENCES 
Browning J.C. (2013). Pediatric morphea. Dermatol Clin 31(2):229-37. 
Fett N. and Werth V.P. (2011). Update on morphea: part I. Epidemiology, clinical presentation 
and pathogenesis. J Am Acad Dermatol. 64(2):217-2. 
Klimas N.K., Shedd A.D., Bernstein I.H., Jacobe H. Health-related quality of life in morphea. Br 
J Dermatol. 2015 May; 172(5):1329-37. 
Leitenberger J.J., Cayce R.L., Haley R.W., Adams-Huet B., Bergstresser P.R., Jacobe H.T. 
(2009). Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. 
Arch Dermatol 145(5):545-50. 
Peterson, L.S., Nelson A.M., Su W.P., Mason T., O’Fallon W.M., Gabriel S.E. (1997). The 
epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993. J Rheumatol 
24(1):73-80. 
Teske N.M., Jacobe H. Using the localized scleroderma cutaneous assessment too (LoSCAT) to 
classify morphoea by severity and identify clinically significant change Br J Dermatol. 2020 Feb; 
182(5): 393-404. 

Protocol FI-SC-01 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
Confidential 
 
Page 54 of 57 
APPENDIX 1. BIOSPY COLLECTION PROCEDURES 
Manufacturing Biopsies 
Biopsies for the purpose of manufacturing are to be obtained from normal or unaffected skin 
with the specific location varying on a case-by-case basis according to the judgment of the 
Investigator. Recommended sites for biopsy include the hip, abdomen, back and/or limbs 
excluding hands/feet, joints, and face. Obtain manufacturing biopsies after all screening 
assessments have been completed and subject is deemed eligible to participate in the study.  
Three 3-4 mm biopsies will be obtained for FCX-013 manufacturing purposes. Additional sets of 
biopsies may be collected if the manufacturing process does not yield an FCX-013 cell count 
sufficient for one administration or do not meet release specifications. 
All medications used must be recorded in the subject’s source documents and CRF.  
Collection Procedures 
1. Anesthetize the area by topical anesthetic, local perfusion. 
2. Prepare the area. 
3. Excise a sample of tissue using the appropriate supplied biopsy punch. The use of forceps 
and a scalpel may be necessary to remove the biopsy from its base. 
4. Gently place excised tissue into cryovial using forceps. 
5. Close donor site as appropriate. 
6. Complete the appropriate forms, as applicable, with subject information. 
7. Package and ship biopsy as described in the Study Procedures Manual, as applicable.  
 

Protocol FI-SC-01 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
Confidential 
 
Page 55 of 57 
APPENDIX 2. INVESTIGATIONAL PRODUCT ADMINISTRATION 
INSTRUCTIONS 
1. The FCX-013 injections are to be administered by the PI or an appropriately trained, 
qualified, and delegated Sub-I. 
2. Administer anesthesia. Subjects will be administered anesthesia per standard of care at 
the Investigative Site. To minimize pain and discomfort during the IP administration, the 
PI or delegated sub-I should determine the most appropriate anesthetic for each subject, 
including the use of topical anesthetic cream, local anesthesia, conscious (moderate) 
sedation, or a combination thereof. In addition, medication could be considered during 
and after the injections to treat pain and/or anxiety (e.g., lorazepam).  
3. Mark the lesional skin to indicate injection points, approximately 1 cm apart, around the 
perimeter of the lesion and across the fibrotic area. 
4. Approximately 15 minutes prior to the administration of FCX-013, remove the subject’s 
treatment vials from the shipper. 
5. Resuspend the cells by gently inverting the injection vial three times. 
6. Tap the top of each vial to release any fluid in the cap prior to opening the vials. Do not 
dilute the product. 
7. Unscrew the cap and, using a detachable bore (21-gauge needle), aseptically draw 1.0 mL 
from one vial.  
8. Once the product is in the syringe, remove the 21-gauge needle and replace it with a 
larger-gauge needle for injection of the product (e.g. – 25 or 27 gauge). Do not use a 21-
gauge needle for injection of the product. Follow sterile technique during this process. 
Note: Living cells are fragile and should be handled gently, especially when being 
aspirated into a syringe. Go slowly and use care during this process.  
9. Hold the syringe using the proper technique: the bevel facing upwards and the arms of 
the syringe are vertical. Some clinicians may prefer to bend the needle upwards at about a 
15-degree angle to facilitate staying in a superficial plane — but use of this technique is 
optional. Grip the syringe with the middle and index finger below the arms, placing the 
thumb on the upper arm. Do not place the thumb on the plunger while directing the 
needle into the skin to avoid premature discharge of the product. 
10. Insert the 25 or 27-gauge needle at the first mark, into or beneath the dermis, at the 
fibrotic area. The graduated markings on the syringe should be visible to ensure that the 
correct amount is being injected. 
11. Slowly inject FCX-013 0.25 mL per linear centimeter, with light pressure on the plunger, 
injecting very tiny boluses (the cells must be injected as delicately as possible) into the 
treatment area as the needle is withdrawn (retro-tracing). The injections should be 
performed intradermally, at the perimeter of the lesion and across and into the fibrotic 
area. Stop injecting before withdrawing the needle and remove your thumb from the 
plunger. 
12. Record any seepage of product or other issues or notes regarding the procedure. 

Protocol FI-SC-01 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
Confidential 
 
Page 56 of 57 
APPENDIX 3. LOCAL SCLERODERMA CUTANEOUS ASSESSMENT 
TOOL (LOSCAT) 
 
 

Protocol FI-SC-01 
FCX-013 
Fibrocell Technologies, Inc 
10-August-2020 
Confidential 
 
Page 57 of 57 
APPENDIX 4. PATIENT REPORTED OUTCOME: SKINDEX 29+3